Supraventricular Tachycardia

On this page

Quick Reference

RxDrug of choiceAdenosine (6 mg IV bolus)

AltAlternativesVerapamil, Diltiazem, Metoprolol, Etripamil (intranasal)

⊘AvoidVerapamil/Diltiazem in pre-excited AFib or HFrEF

DxTest of choice12-lead ECG during tachycardia

ScKey scorePREVENTION-ACHD (for congenital heart disease risk)

→When to referRecurrent episodes, presence of pre-excitation (WPW), or suspected tachycardia-mediated cardiomyopathy

SVT is a common, usually benign narrow-complex tachycardia best managed acutely with the modified Valsalva maneuver or adenosine, and definitively with catheter ablation.

Supraventricular tachycardia (SVT) is a clinical syndrome of rapid, regular tachyarrhythmias originating above the bundle of His, most commonly manifesting as paroxysmal supraventricular tachycardia (PSVT). The three primary mechanisms include atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia (AVRT) involving an accessory pathway, and focal atrial tachycardia (AT). While typically benign, SVT affects 168 to 332 per 100,000 individuals and can lead to tachycardia-mediated cardiomyopathy in approximately 1% of untreated cases. Management has evolved from simple vagal maneuvers to highly effective catheter ablation, which boasts success rates exceeding 94%. In high-risk populations, such as those with Wolff-Parkinson-White (WPW) syndrome or pregnant patients, SVT carries increased risks of sudden cardiac death or adverse maternal-fetal outcomes, necessitating precise diagnosis and targeted intervention.

Overview and Recommendations

Background

•Supraventricular tachycardia (SVT) serves as a clinical umbrella for arrhythmias originating from or conducting through the atria or atrioventricular (AV) node, with (AVNRT) accounting for the majority of cases.
•The prevalence of PSVT ranges from 168 to 332 per 100,000 individuals, showing a distinct female predominance (67%) and a peak incidence between ages 45 and 64, though it can present at any age from infancy to late adulthood.
•Mechanistic classification is critical for management: AVNRT involves a functional circuit within the AV node (slow and fast pathways), while AVRT requires an anatomical as seen in .
•Prognostic stakes are generally low in structurally normal hearts, but untreated chronic tachycardia can lead to reversible tachycardia-mediated cardiomyopathy in 1% of patients and carries a 3.5-fold increased risk of sudden death in patients with .
•Genetic predispositions have been identified, with missense variants in CCDC141 and SCN10A modulating AV conduction and increasing the risk of developing accessory pathways.

Evaluation

•Suspect SVT in patients presenting with the abrupt onset and termination of rapid, regular palpitations, often described as a "flip-flop" or racing sensation in the chest.
•Examine for the "frog sign", visible rapid pulsations in the jugular veins caused by the right atrium contracting against a closed tricuspid valve, which is highly suggestive of AVNRT.
•Order a 12-lead ECG during the episode to differentiate mechanisms; a narrow QRS (<120 ms) confirms a supraventricular origin, while a pseudo-r' wave in lead V1 suggests typical AVNRT.
•Assess for hemodynamic instability, including hypotension, altered mental status, or acute pulmonary edema, which necessitates immediate electrical intervention.
•Evaluate for pre-excitation (delta waves) on a baseline sinus rhythm ECG to diagnose , which carries a risk of malignant .
•Order a (TTE) to rule out structural heart disease, particularly in patients with new-onset heart failure symptoms or suspected tachycardia-mediated cardiomyopathy.
•Utilize ambulatory monitoring (Holter or ) for patients with infrequent, paroxysmal symptoms that are not captured on standard office ECGs.
•Perform an invasive electrophysiological study (EPS) as the gold standard for patients with asymptomatic pre-excitation to identify high-risk pathways (shortest RR interval ≤250 ms during AF).

Management

•Initiate the modified Valsalva maneuver (semi-recumbent strain followed by supine repositioning and passive leg raise) as the first-line physical intervention, as it quadruples conversion rates compared to standard techniques.
•Administer 6 mg rapid IV bolus followed by a saline flush if vagal maneuvers fail; if unsuccessful, escalate to 12 mg and then 18 mg boluses.
•Consider weight-adjusted adenosine dosing (0.1 mg/kg) in obese patients to improve first-dose conversion success, which provides approximately 90% specificity for rhythm restoration.
•Perform immediate synchronized electrical cardioversion (starting at 50-100 J) for any patient with hemodynamic instability or refractory, symptomatic tachycardia.
•Utilize intravenous (5-10 mg over 2 minutes) or (0.25 mg/kg) as second-line agents in stable patients if adenosine is ineffective or contraindicated (e.g., severe asthma).
•Recommend catheter ablation as the definitive first-line therapy for recurrent symptomatic PSVT, given its high success rate (>94%) and low complication profile compared to long-term drug therapy.
•Prescribe oral (e.g., 25-50 mg BID) or for long-term prophylaxis in patients who decline or are not candidates for ablation.
•Manage fetal SVT with transplacental or , which are superior to for converting the fetus to sinus rhythm.
•Administer 0.05 to 0.1 mg/kg for pediatric patients experiencing postoperative junctional ectopic tachycardia (JET) following cardiac surgery.
•Refer patients with asymptomatic pre-excitation for EPS and potential ablation if they are in high-risk professions (e.g., pilots, competitive athletes) or have high-risk conduction properties.
•Avoid non-dihydropyridine calcium channel blockers in patients with suspected pre-excited atrial fibrillation, as they can paradoxically accelerate conduction over the accessory pathway and lead to VF.

Board Review — High Yield

•Frog Sign, Visible jugular venous pulsations in AVNRT due to simultaneous atrial and ventricular contraction.
•Modified Valsalva, Passive leg raise after the strain phase increases success from 17% to 43%.
•Shortest RR Interval ≤250 ms, The critical threshold during AF in WPW patients indicating high risk for ventricular fibrillation.
•Pseudo-r' in V1, ECG finding during tachycardia highly suggestive of typical AVNRT (retrograde P-wave).
•Tachycardia-Mediated Cardiomyopathy, Reversible LV dysfunction occurring when mean heart rate exceeds 100 bpm for prolonged periods.
•Adenosine Dosing, Central line administration requires a lower starting dose (3 mg) due to increased potency.
•Etripamil, An emerging intranasal calcium channel blocker for patient-led, out-of-hospital termination of SVT.
•Orthodromic vs. Antidromic, Orthodromic AVRT (narrow QRS) conducts down the AV node; Antidromic (wide QRS) conducts down the accessory pathway.

Deep Dive — Evidence Details

Definition, Classification, and Nomenclature

▸SVT encompasses tachyarrhythmias originating above the bundle of His, with PSVT affecting up to 332 per 100,000 individuals.
▸The primary mechanisms include AV nodal reentry (AVNRT), AV reentry via accessory pathways (AVRT), and focal or reentrant atrial tachycardia (AT).
▸While generally benign, untreated SVT can cause tachycardia-mediated cardiomyopathy in 1% of patients.

HY High Yield: In patients with asymptomatic pre-excitation (WPW pattern), an electrophysiological study (EPS) can identify high-risk features, such as a shortest RR interval ≤250 ms during atrial fibrillation, which may warrant prophylactic ablation [1, 2].

Supraventricular tachycardia (SVT) is an umbrella term for fast heart rhythms arising from the upper part of the heart. This is in contrast to the other group of fast heart rhythms – ventricular tachycardia, which starts — Supraventricular tachycardia — Supraventricular tachycardia (SVT) is an umbrella term for fast heart rhythms arising from the upper part of the heart. This is in contrast to the oth...Wikipedia ↗

Supraventricular tachycardia (SVT) is a clinical syndrome characterized by tachyarrhythmias that originate from or conduct through the atria or atrioventricular (AV) node, typically presenting with an abrupt onset and termination ^[30]^D5. While the term broadly encompasses any arrhythmia arising above the bundle of His, it is most frequently used to describe paroxysmal supraventricular tachycardia (PSVT), which affects between 168 to 332 per 100,000 individuals ^[30]^D5. These arrhythmias are generally benign but can lead to tachycardia-mediated cardiomyopathy in approximately 1% of cases if left untreated ^[30]^D5.

Synonyms and Abbreviations

PSVT: Paroxysmal Supraventricular Tachycardia
SVT: Supraventricular Tachycardia
PAT: Paroxysmal Atrial Tachycardia (historical term)
Narrow-complex tachycardia: A common clinical descriptor (though SVT may present with wide complexes in the setting of aberrancy)

Classification and Mechanisms

SVT is classified by its electrophysiological mechanism and anatomical circuit. The three most common forms of PSVT are AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT) involving an accessory pathway, and atrial tachycardia (AT) ^[22]^A1a.

Type	Key Distinguishing Feature	Anatomical Substrate
AVNRT	Reentry within the AV node using dual pathways	AV node (Slow and Fast pathways)
AVRT	Reentry using an anatomical accessory pathway	or concealed bypass tract
Atrial Tachycardia	Focal or reentrant circuit within atrial myocardium	Atrial tissue (e.g., right atrial appendage)
Junctional Tachycardia	Automaticity or reentry at the AV junction	AV junctional tissue

Nomenclature and Clinical Variants

Specific variants are defined by their conduction properties and clinical associations. Atypical fast-slow (F/S) AVNRT is a distinct subtype incorporating a "superior" slow pathway located above the Koch triangle, often requiring ablation near the His bundle ^[16]^C4. In pediatric populations, postoperative junctional ectopic tachycardia (JET) is a hemodynamically significant variant occurring after congenital heart surgery ^[23]^A1a.

Clinical significance is often driven by the presence of pre-excitation. Wolff-Parkinson-White (WPW) syndrome refers to the combination of an accessory pathway (pre-excitation on ECG) and symptomatic SVT; in asymptomatic patients with pre-excitation, the risk of malignant (shortest RR interval ≤250 ms) ranges from 0% to 9% ^[1]^A1a^[2]^A1a.

Pearl: SVT is a clinical umbrella, not a single diagnosis; identifying the specific mechanism (AVNRT vs. AVRT vs. AT) is essential because it dictates the success rate of definitive catheter ablation, which exceeds 94% across most subtypes ^[30]^D5.

SVT Classification by Mechanism

Mechanism	Common Subtypes	Clinical Context
Reentrant	AVNRT, AVRT, Atrial Flutter	Abrupt onset/offset; most common PSVT form
Automatic	Focal Atrial Tachycardia, JET	Often associated with metabolic stress or surgery
Triggered	Some forms of Atrial Tachycardia	Related to delayed afterdepolarizations

Epidemiology and Risk Factors

▸SVT is a significant driver of morbidity in specialized populations, including a 7% incidence following heart transplantation and a 24% incidence in pediatric cardiac tumors.
▸Cannabis use is associated with a 71% increased risk of atrial arrhythmias, including SVT.
▸In patients with congenital heart disease, the presence of SVT increases the odds of sudden cardiac death 3.5-fold.

HY High Yield: In asymptomatic patients with Wolff-Parkinson-White (WPW) patterns, the risk of sudden cardiac death is low (1.25 per 1000 person-years), but the risk of developing SVT is higher at 16 events per 1000 person-years [32].

The prevalence and incidence of supraventricular tachycardia (SVT) vary significantly across clinical contexts, ranging from rare congenital anomalies to common postoperative complications. In the general outpatient setting, clinically significant tachyarrhythmias are relatively uncommon; among patients presenting with palpitations and structurally normal hearts, the prevalence of SVT is approximately 0.8% ^[49]^B2b. However, in specialized populations, such as those with , inappropriate shocks from implantable cardioverter-defibrillators (ICDs) are triggered by SVT in 5.3% to 9.5% of cases ^[14]^B2b^[15]^B2b.

Demographic Distribution

SVT exhibits distinct patterns across age groups and sexes:

Infants: Most pediatric cases are diagnosed at ≤60 days of age (median 13 days), with a notable male predominance of 62% ^[17]^B3b.
Adults: In patients with asymptomatic pre-excitation, the majority are male (50% to 74%) with a median age range of 19 to 36 years ^[1]^A1a^[2]^A1a.
Pregnancy: Maternal arrhythmias are increasingly prevalent with advanced maternal age ^[45]^B2a. SVT during pregnancy is independently associated with an increased risk of preeclampsia (aRR 1.14), preterm delivery (aRR 1.76), and small-for-gestational-age neonates (aRR 5.93) ^[45]^B2a.

Risk Factors and Clinical Drivers

Risk factors for SVT include both structural cardiac abnormalities and modifiable lifestyle factors. In patients with , SVT is a potent predictor of (OR 3.5) ^[12]^B3b.

Factor	Association/Effect	Evidence Level
Cannabis Use	71% increased risk of atrial arrhythmias ^[44]^B2a	2a
Congenital Heart Disease	OR 3.5 for sudden cardiac death ^[12]^B3b	3b
Infective Endocarditis	OR 3.29 for development of septic shock ^[41]^B2b	2b
	24% of pediatric patients (highest in fibromas) ^[19]^C4	4
Heart Transplantation	7% incidence in stable post-OHT patients ^[37]^B3b	3b
Thoracoscopic Surgery	33.3% incidence of new-onset SVT postoperatively ^[47]^A1b	1b

Genetic and Structural Predispositions

Recent genome-wide association studies have identified common missense variants in CCDC141 and SCN10A associated with accessory atrioventricular pathways and paroxysmal SVT ^[50]^B3b. These variants often correlate with a shorter PR interval and higher heart rate ^[50]^B3b. Structural triggers include rare anomalies such as right atrial appendage aneurysms, which present with atrial arrhythmias in 31.8% of cases ^[27]^C4.

Temporal and Procedural Trends

Postoperative SVT is a frequent complication of cardiothoracic interventions. In pediatric patients following congenital heart surgery, junctional ectopic tachycardia (JET) is a hemodynamically consequential event ^[23]^A1a. In adults undergoing thoracoscopic surgery for lung cancer, the incidence of new-onset SVT in the first 24 hours is 33.3%, though this may be reduced to 10.5% through perioperative interventions like electroacupuncture ^[47]^A1b. Long-term treatment with in patients with type 2 diabetes has been shown to reduce the risk of SVT and other atrial arrhythmias ^[43]^A1a.

Pearl: In infants, the risk of SVT recurrence is 33%, with the highest risk seen in those with or those requiring second-line therapy ^[17]^B3b.

SVT Recurrence and Complication Risks

Population	Event	Rate/Risk	Source
Infants	SVT Recurrence	33%	^[17]^B3b
Asymptomatic Pre-excitation	Sudden Cardiac Death	1.25 per 1000 person-years	^[32]^B2a
Brugada Syndrome (ICD)	Inappropriate Shock (SVT)	5.3% - 9.5%	^[14]^B2b^[15]^B2b
Post-Thoracoscopic Surgery	New-onset SVT	33.3%	^[47]^A1b

Pathophysiology and Mechanism

▸Reentry is the dominant mechanism for PSVT, requiring dual pathways with heterogeneous electrophysiological properties.
▸Genetic variants in CCDC141 and SCN10A are linked to accessory pathways and increased PSVT risk.
▸Sustained SVT with a mean heart rate >100 bpm can lead to reversible arrhythmia-induced cardiomyopathy.

HY High Yield: In patients with heart transplants, atrial fibrillation is rare in stable conditions; its presence should prompt immediate evaluation for acute rejection or transplant vasculopathy [37].

Supraventricular tachycardia (SVT) arises from discrete electrophysiological perturbations within the atria or atrioventricular (AV) junction that permit rapid, self-sustaining electrical activity. These mechanisms are broadly categorized into reentry, which requires a circuit of heterogeneous conduction, and enhanced automaticity or triggered activity, which involves focal impulse generation ^[30]^D5.

Reentrant Mechanisms

Reentry is the most common mechanism for paroxysmal SVT (PSVT), necessitating two distinct pathways with different refractory periods and conduction velocities ^[30]^D5.

AV Nodal Reentrant Tachycardia (AVNRT): This involves a functional circuit within the . A "slow" pathway (short refractory period, slow conduction) and a "fast" pathway (long refractory period, rapid conduction) create the substrate. An appropriately timed premature atrial contraction (PAC) may find the fast pathway refractory, conduct down the slow pathway, and then retrogradely ascend the fast pathway once it has recovered, initiating the circuit ^[30]^D5. Atypical variants, such as fast-slow AVNRT, may incorporate a "superior" slow pathway located above the Koch triangle near the His bundle ^[16]^C4.
AV Reentrant Tachycardia (AVRT): This requires an anatomical (AP) that bypasses the AV node. In orthodromic AVRT, the impulse conducts anterogradely through the AV node and retrogradely through the AP. In antidromic AVRT, the circuit is reversed. Genetic variants in CCDC141 and SCN10A are associated with the presence of APs and may modulate heart rate and AV conduction velocity, increasing the risk of PSVT ^[50]^B3b.
Macro-reentrant Atrial Tachycardia: Common in patients after heart transplantation (9% incidence of ), these circuits often involve surgical scars or the cavotricuspid isthmus ^[37]^B3b.

Focal and Triggered Mechanisms

Focal SVTs result from abnormal impulse formation at a single site.

Enhanced Automaticity: Cells outside the depolarize spontaneously at a rate faster than the sinus rhythm.
Triggered Activity: This involves delayed afterdepolarizations (DADs) or early afterdepolarizations (EADs). For example, increased intracellular calcium overload can lead to electrical instability ^[33]^A1b. In calcium release deficiency syndrome (CRDS), a pathologically large systolic release of calcium from the sarcoplasmic reticulum causes a unique repolarization response after brief tachycardia and a subsequent pause ^[31]^B3b.

Autonomic and Environmental Modifiers

Autonomic tone significantly influences SVT initiation and termination. Vagal maneuvers, such as the , increase parasympathetic tone to slow AV nodal conduction and terminate reentrant circuits ^[51]^A1b^[54]^A1a. Conversely, sympathetic stimulation from substances like is associated with a 71% increased risk of atrial arrhythmias (95% CI 1.1-2.6) ^[44]^B2a.

Tachycardia-Induced Remodeling

Persistent SVT can lead to structural and functional changes in the myocardium:

Arrhythmia-Induced Cardiomyopathy (AiCM): Sustained heart rates >100 beats/min can induce a reversible dilated cardiomyopathy ^[8]^D5^[9]^D5.
Atrial Remodeling: Chronic SVT or leads to histopathological changes, though women may exhibit lower atrial voltages than men due to smaller atrial mass rather than more severe fibrosis ^[53]^B3b.

Mechanism flowchart

Pearl: The distinction between AVNRT and AVRT rests on whether the reentrant circuit is confined to the AV node or requires an extranodal accessory pathway; both typically require a premature beat to initiate the circuit ^[30]^D5^[50]^B3b.

Comparison of Reentrant SVT Mechanisms

Mechanism	Circuit Location	Key Substrate	Initiation Trigger
AVNRT	AV Nodal Region	Dual pathways (Fast/Slow)	PAC finding fast pathway refractory ^[30]^D5
AVRT	AV Node + Accessory Pathway	Anatomical bypass tract	PAC or PVC ^[30]^D5^[50]^B3b
Atrial Flutter	Atrial Myocardium	Cavotricuspid isthmus or scar	Atrial premature beat ^[37]^B3b

Clinical Presentation

▸Palpitations are the most common symptom (86%), but nearly half of patients (47%) experience chest discomfort during episodes.
▸Tachycardia-mediated cardiomyopathy is a rare (1%) but reversible complication that should be suspected when the mean heart rate exceeds 100 beats/min.
▸In infants, SVT often presents non-specifically with poor feeding or irritability and is most frequently diagnosed within the first 60 days of life.

HY High Yield: The 'Frog Sign' (visible jugular venous pulsations) is a specific physical exam finding for AVNRT, caused by simultaneous atrial and ventricular contraction against a closed tricuspid valve.

! Warning: In patients with WPW, a shortest RR interval ≤250 ms during atrial fibrillation is a critical threshold for high risk of sudden cardiac death [1].

The clinical presentation of supraventricular tachycardia (SVT) is characterized by the abrupt onset of rapid, regular palpitations, often described by patients as a sudden "flip-flop" or racing sensation in the chest ^[30]^D5. While the majority of patients are female (67.5%) and aged 45 to 64 years (50%), the presentation varies significantly across the lifespan, from fetal life to old age ^[30]^D5.

Presenting Symptoms

Symptoms are primarily driven by the rapid ventricular rate and the loss of atrioventricular synchrony, which reduces diastolic filling time and cardiac output.

Palpitations: Reported by 86% of patients; typically sudden onset and termination ^[30]^D5.
Chest Discomfort: Occurs in 47% of patients, often mimicking angina due to increased myocardial oxygen demand ^[30]^D5.
Dyspnea: Reported by 38% of patients ^[30]^D5.
Syncope and Presyncope: While less common, syncope may occur at the onset of tachycardia before vascular compensation occurs, or in patients with concomitant ^[26]^A1b.
Polyuria: Occasionally noted due to the release of atrial natriuretic peptide in response to elevated atrial pressures.

Physical Examination Findings

During an acute episode, the clinician may observe several pathognomonic or suggestive signs:

Tachycardia: A rapid, regular pulse typically ranging from 150 to 250 beats/min.
Frog Sign: Visible rapid pulsations in the jugular veins, caused by the right atrium contracting against a closed tricuspid valve (common in ) ^[30]^D5.
Hypotension: May occur if the rate is sufficiently high to compromise stroke volume or if structural heart disease is present.
Signs of Heart Failure: Crackles or S3 gallop may be present if the episode is prolonged, leading to acute decompensation.

Phenotypic Variants and Special Populations

Population/Variant	Key Features	Frequency/Context
Infants	Irritability, poor feeding, pallor, or tachypnea; 62% are male ^[17]^B3b.	87% diagnosed at ≤60 days ^[17]^B3b.
Pregnancy	Symptomatic palpitations; may require for diagnosis ^[11]^A1b.	Higher risk of preterm delivery ^[11]^A1b.
Post-Transplant	Often macro-reentrant ( /scar reentry); AF suggests rejection ^[37]^B3b.	Atrial flutter in 9% of OHT patients ^[37]^B3b.
Adult Congenital Heart Disease	Associated with increased risk of (OR 3.5) ^[12]^B3b.	19% of deaths in ACHD are sudden ^[12]^B3b.

Red Flags and Complications

Certain features necessitate urgent intervention or suggest a higher risk of adverse outcomes:

Hemodynamic Instability: Hypotension, altered mental status, or acute pulmonary edema requires emergent electrical cardioversion ^[30]^D5^[59]^D5.
Tachycardia-Mediated Cardiomyopathy: Should be suspected if the mean heart rate is >100 beats/min with associated left ventricular dysfunction; occurs in approximately 1% of PSVT patients ^[8]^D5^[30]^D5.
Pre-excitation (WPW): In patients with asymptomatic pre-excitation, the development of malignant (shortest RR interval ≤250 ms) carries a risk of ventricular fibrillation (0% to 2%) ^[1]^A1a.

ECG Findings

Finding	Mechanism	Significance
Narrow QRS (<120 ms)	Normal ventricular activation via the His-Purkinje system.	Confirms supraventricular origin.
Wide QRS (≥120 ms)	Pre-existing or rate-related aberrancy ^[21]^B2b.	May be mistaken for ventricular tachycardia.
Pseudo-r' in V1	Retrograde P-wave buried in or at the end of the QRS.	Highly suggestive of typical AVNRT.
Delta Wave	Early ventricular activation via an accessory pathway.	Diagnostic of .

Pearl: In patients with a pre-existing bundle branch block, the QRS morphology can change significantly during SVT without implying a ventricular origin; however, a change to the contralateral bundle branch pattern during tachycardia strongly suggests ventricular tachycardia ^[21]^B2b.

SVT Presentation in Special Populations

Population	Clinical Nuance	Evidence
Infants	33% recurrence rate; highest risk in those with WPW or late diagnosis (>60 days).	^[17]^B3b
Heart Transplant	Adenosine is effective but should be started at low doses (25 μg/kg) to avoid prolonged asystole.	^[6]^B2b
Brugada Syndrome	SVT can trigger inappropriate ICD shocks in up to 20-24% of patients.	^[14]^B2b^[15]^B2b
Cardiac Tumors	24% of pediatric patients with cardiac tumors (especially fibromas) develop significant arrhythmias.	^[19]^C4

Diagnosis and Workup

▸The 12-lead ECG is the primary diagnostic modality, with pseudo-s' or pseudo-r' waves being highly specific for AVNRT.
▸Extended 72-hour Holter monitoring doubles the detection rate of SVT compared to 24-hour monitoring in symptomatic patients.
▸Invasive electrophysiological study is the gold standard for risk-stratifying asymptomatic pre-excitation, where a shortest RR interval ≤250 ms during AFib indicates high risk.

Dx Diagnostic Essentials: The 12-lead ECG during an active episode is the definitive bedside diagnostic tool for classifying SVT mechanism based on QRS width and RP relationship.

HY High Yield: Elevated ionized calcium levels independently increase the likelihood of successful conversion with adenosine (OR 1.41), whereas heart failure and prior antiarrhythmic use reduce efficacy [64].

Establishing the diagnosis of supraventricular tachycardia (SVT) requires capturing the arrhythmia on a 12-lead electrocardiogram (ECG) to differentiate between reentrant and automatic mechanisms. While the clinical presentation often involves paroxysmal palpitations, dyspnea (38%), or chest discomfort (47%), the definitive workup focuses on identifying the specific circuit or focus to guide definitive catheter-based ^[30]^D5.

History and Physical

Clinical evaluation focuses on the onset, duration, and termination of episodes.

Paroxysmal Onset: Sudden start and stop are characteristic of paroxysmal supraventricular tachycardia (PSVT) ^[30]^D5.
Triggers: High-dose caffeine from energy drinks or tablets can provoke SVT, particularly in adolescents ^[65]^A1a. Blunt chest trauma may unmask occult conduction abnormalities like ^[69]^C4.
Physical Signs: Rapid, regular pulses are typical. Hemodynamic instability (hypotension, altered mentation) upgrades the urgency to emergent cardioversion ^[30]^D5.
Red Flags: Syncope in the presence of SVT may indicate underlying structural heart disease or high-risk accessory pathways ^[12]^B3b^[20]^B2b.

ECG Findings

The 12-lead ECG during tachycardia is the primary diagnostic tool. Key features include a regular narrow-QRS rhythm (typically 150-250 bpm) ^[30]^D5.

Finding	Mechanism	Significance
Short RP Interval	Retrograde conduction via fast pathway	Suggests typical AVNRT or AVRT via a fast accessory pathway ^[16]^C4^[30]^D5.
Long RP Interval	Retrograde conduction via slow pathway	Suggests atypical AVNRT, permanent form of junctional reciprocating tachycardia (PJRT), or atrial tachycardia ^[16]^C4.
Delta Wave	Ventricular pre-excitation	Diagnostic of during sinus rhythm ^[1]^A1a^[69]^C4.
Pseudo-s' or Pseudo-r'	Retrograde P-wave in V1 or II	Highly suggestive of atrioventricular nodal reentrant tachycardia (AVNRT) ^[30]^D5.
Wide QRS (>120 ms)	Aberrancy or pre-excitation	Requires differentiation from ventricular tachycardia; pre-existing bundle branch block (BBB) can cause major QRS morphology changes during SVT ^[21]^B2b.

Laboratory and Imaging

Biochemical Markers: Elevated ionized calcium levels are associated with increased odds of successful conversion (OR 1.41 per 0.1 mmol/L) ^[64]^B3b.
Echocardiography: Indicated to rule out structural heart disease, such as (found in 80% of cases with SVT) or right atrial appendage aneurysms ^[27]^C4^[62]^C4. It is essential for identifying tachycardia-mediated cardiomyopathy, which occurs in approximately 1% of PSVT patients ^[30]^D5.
Ambulatory Monitoring: For patients with infrequent symptoms, 24-hour Holter monitoring detects SVT in 4.1% of post-stroke patients, while extended 72-hour monitoring doubles the detection rate to 8.8% ^[67]^B2b. In pregnant patients, implantable loop recorders (ILR) are superior to Holter monitoring, detecting arrhythmias in 53% vs 24% of symptomatic patients ^[11]^A1b.

Gold-Standard Test: Electrophysiological Study (EPS)

Invasive EPS remains the gold standard for definitive diagnosis and risk stratification. It is specifically indicated for patients with asymptomatic pre-excitation to determine the shortest RR interval during ; an interval ≤250 ms identifies patients at high risk for ventricular fibrillation ^[1]^A1a. EPS can differentiate complex cases, such as atypical fast-slow AVNRT incorporating a superior slow pathway near the His bundle, from other long-RP tachycardias ^[16]^C4.

Diagnostic Algorithm

Pearl: In patients with pre-existing bundle branch block, a change in QRS morphology during tachycardia does not necessarily imply ventricular tachycardia, as rate-related aberrancy is common ^[21]^B2b.

Diagnostic Performance of Monitoring Modalities

Modality	Population	Detection Rate	Clinical Impact
24-hour Holter	Post-stroke/TIA	4.1%	Baseline detection ^[67]^B2b
72-hour Holter	Post-stroke/TIA	8.8%	Doubled detection rate ^[67]^B2b
Implantable Loop Recorder	Symptomatic Pregnancy	53%	Changed management in 43% ^[11]^A1b
12-Lead ECG (CNN-based)	General Adult	AUC ≥0.96	High sensitivity for rhythm ^[29]^B2c

Severity Staging and Risk Stratification

▸Asymptomatic pre-excitation carries a 0% to 2% risk of ventricular fibrillation, with the highest risk observed in children.
▸The PREVENTION-ACHD score identifies high-risk congenital heart disease patients using SVT as one of seven key prognostic variables.
▸In patients with heart failure, new-onset SVT is associated with a >6-fold increase in all-cause mortality.

HY High Yield: In pediatric patients with Brugada syndrome, fever is the most important precipitating factor for arrhythmic events, especially in those with a spontaneous Type I ECG pattern [13].

Risk stratification in supraventricular tachycardia (SVT) focuses on identifying patients at risk for life-threatening arrhythmic events (LAEs), particularly those with pre-excitation or underlying structural and genetic heart diseases. While many SVT episodes are benign, their presence often serves as a marker for increased mortality or the development of complex arrhythmias like (AF) ^[1]^A1a^[72]^B2b.

Asymptomatic Pre-excitation

In patients with asymptomatic pre-excitation, risk stratification via electrophysiological study (EPS) is utilized to identify high-risk accessory pathways. In observational cohorts of asymptomatic patients not undergoing ablation, regular SVT or benign AF (shortest RR interval >250 ms) developed in 0% to 16%, while malignant AF (shortest RR interval ≤250 ms) occurred in 0% to 9% ^[1]^A1a^[2]^A1a. Ventricular fibrillation (VF) was rare, occurring in 0% to 2%, primarily in pediatric populations ^[1]^A1a. A randomized trial demonstrated that catheter ablation in high-risk asymptomatic patients reduced the 5-year incidence of arrhythmic events from 77% to 7% (relative risk reduction: 0.08; 95% CI: 0.02 to 0.33; P<0.001) ^[1]^A1a^[2]^A1a.

Prognostic Scores and Risk Models

Specific scoring systems and clinical variables help predict (SCD) and other adverse outcomes in patients with SVT and comorbid conditions.

PREVENTION-ACHD Risk Score: Used for adults with congenital heart disease (ACHD). It assigns 1 point each to coronary artery disease, II/III heart failure, SVT, systemic EF <40%, subpulmonary EF <40%, QRS duration ≥120 ms, and QT dispersion ≥70 ms ^[74]^B2b. An annual predicted risk of ≥3% defines high risk. High-risk patients had a significantly higher rate of SCD or VT/VF compared to low-risk patients (7% vs 0.6%; HR 12.5; P <.001) ^[74]^B2b.
Modified Gollob Score: In pediatric patients with short QT syndrome (SQTS), a modified Gollob score (excluding clinical events) of 5 or more is associated with a higher likelihood of clinical events, whereas those with a score <5 often remain event-free ^[18]^C4.
Infective Endocarditis (IE) Risk: SVT is an independent predictor for the development of septic shock in patients with IE (OR: 3.29) ^[41]^B2b.

Risk of Atrial Fibrillation and Mortality

Frequent supraventricular ectopy and SVT burden are linked to long-term morbidity. In patients with mild heart failure, new-onset SVT is associated with a >4-fold increased risk for ventricular tachyarrhythmic events and a >6-fold increased risk for all-cause mortality ^[72]^B2b. High SVT burden (≥20 episodes) further escalates mortality risk compared to low burden ^[72]^B2b. Additionally, combining frequent supraventricular extrasystoles (SVEs) with elevated NT-proBNP levels significantly improves the prediction of incident AF (HR 4.61) compared to using either marker alone ^[75]^B2b.

ECG Findings in Risk Stratification

Finding	Mechanism	Clinical Significance
Shortest RR Interval ≤250 ms	Rapid conduction over accessory pathway	High risk for VF during AF ^[1]^A1a
Spontaneous Type I Pattern	Sodium channel dysfunction in	Higher risk of arrhythmic events in children ^[13]^C4
Inferolateral ERP	Early repolarization in ERS	Poorer prognosis than inferior ERP alone (HR 9.29) ^[73]^B3b
SVT in IVF	Coexistence of SVT in idiopathic VF	Risk factor for life-threatening arrhythmic events (HR 7.24) ^[73]^B3b

Pearl: In asymptomatic patients with pre-excitation, a shortest RR interval of ≤250 ms during AF is a critical threshold for identifying those at high risk for ventricular fibrillation, warranting consideration for invasive EPS and ablation ^[1]^A1a^[2]^A1a.

Predictors of Septic Shock in Infective Endocarditis

Variable	Odds Ratio (OR)	95% Confidence Interval
Supraventricular Tachycardia	3.29	1.14-9.44
Staphylococcus aureus	2.97	1.72-5.15
Acute Renal Insufficiency	3.22	1.28-8.07
Diabetes Mellitus	2.06	1.16-3.68
Persistent Infection Signs	9.8	5.48-17.52

Acute and Initial Management

▸The modified Valsalva maneuver (semi-recumbent with passive leg raise) achieves a 43% conversion rate compared to 17% for the standard maneuver (NNT = 4).
▸Intravenous adenosine is 91% effective for acute termination, though a fixed 6 mg dose may be insufficient in patients with higher body weight.
▸Etripamil nasal spray (70 mg) is an emerging self-administered option that converts 64% of episodes within 30 minutes.

Rx Drug of Choice: Intravenous [[adenosine]] (6 mg rapid bolus followed by a saline flush) is the first-line pharmacological agent for stable SVT, with a 91% success rate [30].

! Warning: Immediate synchronized electrical cardioversion is required for any patient with SVT and hemodynamic instability (hypotension, pulmonary edema, or ischemia) [30].

Acute stabilization of supraventricular tachycardia (SVT) prioritizes the restoration of sinus rhythm through a stepwise escalation from non-invasive vagal maneuvers to pharmacological or electrical cardioversion. While the condition is generally benign, untreated episodes can lead to tachycardia-mediated in approximately 1% of patients ^[30]^D5 (5). In the emergency setting, the choice of intervention is dictated by hemodynamic stability and the underlying mechanism of the arrhythmia.

Step 1: Hemodynamic Assessment and Vagal Maneuvers

For hemodynamically stable patients, vagal maneuvers remain the first-line intervention. The standard Valsalva maneuver (VM) often yields suboptimal success rates, ranging from 5% to 20% ^[51]^A1b.

Step 2: First-Line Pharmacological Therapy

If vagal maneuvers fail, intravenous is the preferred agent due to its rapid onset and high efficacy (91%) ^[30]^D5 (5).

Dosing and Weight Considerations: While guidelines recommend a fixed initial dose of 6 mg, rising obesity rates may impair efficacy. Successful conversion is associated with a significantly higher weight-adjusted dose (0.082 mg/kg vs. 0.074 mg/kg in failures; p < 0.001) ^[86]^B2b. A weight-adjusted dose of ≥ 0.10 mg/kg provides 90.8% specificity for predicting conversion ^[86]^B2b.

Step 3: Second-Line and Refractory

In patients refractory to or those with contraindications (e.g., severe ), intravenous calcium channel blockers or beta-blockers are utilized. For hemodynamically unstable patients (e.g., hypotension, altered mental status, or ), immediate synchronized electrical cardioversion is mandatory ^[30]^D5 (5).

Step 4: Special Clinical Contexts

Fetal SVT: Transplacental therapy using or is effective in 90% of cases ^[34]^B2b. and are superior to for converting fetal SVT to sinus rhythm (HR 2.1 and 2.9, respectively) ^[79]^B2b.
Postoperative JET: In pediatric patients with junctional ectopic tachycardia after cardiac surgery, (0.05 to 0.1 mg/kg) has shown a pooled conversion rate of 98.8% (95% CI 93.8-100) ^[23]^A1a.
Critical Care: Protocolized supplementation (threshold ≤ 0.95 mmol/L) is associated with a 1.6% absolute risk reduction in the 24-hour incidence of or flutter ^[84]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Initial Adenosine Dosing	Standard Guidelines, Recommend a fixed 6 mg initial bolus ^[30]^D5^[86]^B2b	Emerging Evidence, Suggests weight-adjusted dosing (0.1 mg/kg) to account for body mass ^[86]^B2b	Moderate	Fixed dosing may lead to higher failure rates in obese patients, necessitating repeat doses.
Prehospital Discharge	Traditional Practice, Transport all SVT patients to the ED after conversion ^[82]^B3b	Treat and Discharge Protocols, Allow paramedics to discharge patients if SVT is resolved ^[82]^B3b	Mild	Paramedic discharge reduces ED utilization and call duration (45 vs 87 min) but is currently used in only 2.2% of eligible cases ^[82]^B3b.

Pearl: The modified Valsalva maneuver with passive leg raise should be the first-line intervention for stable SVT, as it quadruples the odds of conversion compared to the standard technique (NNT = 4) ^[51]^A1b.

Acute Pharmacological Management of SVT

Starting Dose	Target/Max Dose	Key Trial	Outcome	Evidence Level
6 mg IV bolus	12 mg repeat dose	Satici et al. ^[86]^B2b	58.1% first-dose success	2b
70 mg intranasal	140 mg (repeat at 10 min)	RAPID ^[78]^A1b	64% conversion at 30 min	1b
0.05 mg/kg PO/NG	0.1 mg/kg BID	Balweel et al. ^[23]^A1a	98.8% conversion (JET)	1a
Weight-based	Per serum levels	Jaeggi et al. ^[79]^B2b	Superior to sotalol in fetal SVT	2b

Long-term Guideline-Directed Therapy

▸Catheter ablation provides a definitive cure for PSVT in over 94% of cases and is superior to long-term pharmacotherapy for preventing recurrences.
▸Self-administered intranasal etripamil (70 mg) offers a rapid, non-invasive option for acute termination of SVT episodes outside the hospital setting.
▸Asymptomatic pre-excitation requires individualized risk stratification, as ablation reduces the 5-year risk of arrhythmic events from 77% to 7% in high-risk individuals.

Rx Drug of Choice: Catheter ablation is the preferred long-term management strategy for symptomatic PSVT due to its high success rate (>95%) and low complication profile compared to lifelong antiarrhythmic therapy [30, 42].

! Warning: In patients with an implantable cardioverter-defibrillator (ICD), SVT is a common cause of inappropriate shocks (36% of inappropriate episodes in MADIT II), which are associated with a hazard ratio of 2.29 for all-cause mortality [38].

Long-term of supraventricular tachycardia (SVT) focuses on preventing recurrence and mitigating the risk of , which can occur in approximately 1% of patients with chronic or frequent episodes ^[30]^D5^[9]^D5. While acute stabilization relies on vagal maneuvers and , definitive long-term care is increasingly centered on catheter ablation due to its high curative potential and the limited evidence for the long-term efficacy of pharmacotherapy ^[30]^D5.

Catheter Ablation

Catheter ablation is recommended as first-line therapy to prevent recurrence of paroxysmal SVT (PSVT) ^[30]^D5. Meta-analyses of observational studies demonstrate single-procedure success rates between 94.3% and 98.5% ^[30]^D5. In the German Ablation Quality Registry (n=12,566), periprocedural success was 96.3% overall, with subtype-specific rates of 98.9% for (AVNRT) and 84.3% for focal atrial tachycardia ^[42]^B2b.

Patient Satisfaction: Approximately 74.1% of patients perceive ablation as successful after 1 year ^[42]^B2b.
Recurrence: Recurrence of the ablated or a new symptomatic SVT occurs in 32.6% of patients within 1 year, ranging from 17.2% in AVNRT to 45.6% in ^[42]^B2b.
Safety: Ablation is generally safe, though subtle post-procedural cognitive dysfunction (POCD) has been noted in 3% of SVT ablation patients at 90 days, significantly lower than the 13% to 20% seen after atrial fibrillation ablation ^[36]^B2b.

Pharmacological Prophylaxis

For patients who decline ablation or are not candidates, long-term pharmacotherapy is utilized to reduce the frequency and severity of episodes. Guidelines recommend , , and various antiarrhythmic agents ^[30]^D5.

Standard Agents: , , and are commonly employed for rate and rhythm control ^[17]^B3b^[89]^C4.
Novel Therapies: has demonstrated potential antiarrhythmic effects; in the MERLIN- 36 trial, it reduced the incidence of SVT compared to placebo (44.7% vs 55.0%, P<0.001) ^[33]^A1b.

Management in Special Populations

Asymptomatic Pre-excitation: In patients with asymptomatic , the risk of (SCD) is estimated at 1.25 per 1000 person-years ^[32]^B2a. A randomized trial of ablation vs. observation in high-risk asymptomatic patients showed a 5-year arrhythmia incidence of 7% with ablation vs. 77% without (RRR 0.08, 95% CI 0.02-0.33, P<0.001) ^[1]^A1a^[2]^A1a.
Pregnancy: SVT management during pregnancy is challenging. While is often used first-line, zero-x-ray using three-dimensional intracardiac ultrasound guidance is a safe and effective option in the second or third trimester ^[89]^C4^[94]^D5.
Pediatrics: In infants with re-entrant SVT, 33% experience recurrence ^[17]^B3b. Risk factors include WPW syndrome (HR 2.46) and the need for multi-drug therapy (HR 2.08) ^[17]^B3b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Management of Asymptomatic WPW	ACC/AHA/HRS, Suggests risk stratification with EPS may be beneficial for high-risk substrate ^[1]^A1a^[2]^A1a	Meta-analysis (Obeyesekere et al.), Argues against routine invasive management due to low SCD incidence (1.25/1000 person-years) ^[32]^B2a	Moderate	Clinicians must balance the low absolute risk of SCD against the high relative risk reduction of ablation in selected patients.

Pearl: Catheter ablation is the definitive first-line therapy for PSVT with success rates exceeding 95%, whereas long-term pharmacotherapy is primarily reserved for patients who are not candidates for or decline invasive intervention ^[30]^D5^[42]^B2b.

Long-term Pharmacotherapy Options for SVT

Indication	Key Evidence	Outcome	Evidence Level
Maintenance prophylaxis	Standard of care ^[89]^C4	Rate control and symptom reduction	4
Adjunctive prophylaxis	MERLIN-TIMI 36 ^[33]^A1b	Reduced SVT incidence (44.7% vs 55.0%)	1b
Postoperative JET	Meta-analysis ^[23]^A1a	98.8% conversion to sinus rhythm	1a

Dosing and Monitoring for Long-term SVT Agents

Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
70 mg intranasal	140 mg (repeat once at 10 min)	Not reported	Not reported	Local irritation, BP
0.05 mg/kg BID	0.1 mg/kg BID	Not reported	Not reported	Heart rate, ECG
0.5 mg daily	0.5 mg daily	Not reported	Not reported	HR (first-dose SVT risk) ^[7]^A1b

Interventional and Device Therapy

▸Catheter ablation is first-line therapy for preventing SVT recurrence, with success rates between 94.3% and 98.5% [30].
▸Inappropriate ICD shocks for SVT are common (11.5%) and can be reduced by nearly 50% using dual-chamber detection enhancements [3, 38].
▸Ablation in asymptomatic pre-excitation (WPW) significantly reduces 5-year arrhythmic risk from 77% to 7% [1, 2].

HY High Yield: In pediatric patients, a 30-minute post-ablation waiting period provides an absolute risk reduction of 3.0% in follow-up recurrence for manifest accessory pathways [99].

! Warning: Inappropriate ICD shocks for SVT are associated with a hazard ratio of 2.29 for all-cause mortality, though the risk may be related to the underlying arrhythmia rather than the shock itself [38, 40].

Long-term of supraventricular tachycardia (SVT) often transitions from pharmacological suppression to definitive interventional strategies, primarily , which is recommended as first-line therapy to prevent recurrence ^[30]^D5. While medications like and remain options, ablation offers high curative potential with single-procedure success rates ranging from 94.3% to 98.5% ^[30]^D5.

Step 1: Electrophysiological Study and Risk Stratification

Invasive electrophysiological study (EPS) is indicated for symptomatic patients and high-risk asymptomatic individuals with pre-excitation. In patients with asymptomatic Wolff-Parkinson-White (WPW) pattern, the risk of (SCD) is estimated at 1.25 per 1000 person-years (95% CI, 0.57-2.19) ^[32]^B2a.

Asymptomatic Pre-excitation: Ablation reduces the 5-year incidence of arrhythmic events from 77% to 7% (RRR 0.08; 95% CI, 0.02-0.33; P<0.001) ^[1]^A1a^[2]^A1a.
Induction Indices: When tachycardia is non-sustained, the induction postpacing interval (iPPI) minus tachycardia cycle length (TCL) can differentiate mechanisms. A corrected iPPI-TCL ≤110 ms identifies orthodromic reciprocating tachycardia (ORT) with 90.2% sensitivity and 100% specificity ^[100]^B3b.

Step 2: Catheter Ablation

( ) is the standard of care for most SVT subtypes, though and (PFA) are emerging for anatomically challenging pathways ^[97]^C4.

AVNRT: Periprocedural success is highest for atrioventricular nodal reentrant tachycardia at 98.9% ^[42]^B2b. Atypical fast-slow AVNRT incorporating a superior slow pathway near the His bundle can be successfully eliminated via RFA ^[16]^C4.
: Success rates are high, but these patients exhibit higher 1-year mortality (2.6%) and stroke rates compared to other SVT groups, necessitating long-term anticoagulation ^[42]^B2b.
Pediatric Populations: In children <15 kg and <5 years, acute success is approximately 94% ^[85]^D5. Older age at the time of procedure is a significant independent predictor of long-term success ^[96]^B3b.

Step 3: Device Programming and Management

In patients with implantable cardioverter-defibrillators (ICDs), SVT is a leading cause of inappropriate shocks, occurring in 11.5% of patients in the MADIT II cohort ^[38]^B2b.

Detection Enhancements: Dual-chamber ICDs reduce the odds of inappropriate SVT detection by nearly half (OR 0.53; 95% CI, 0.30-0.94; P=0.03) compared to single-chamber devices ^[3]^A1b.
Standardized Programming: Empiric programming (e.g., detection rates ≥182 bpm for 30 of 40 beats) reduces shocks from 17% to 9% (p < 0.01) ^[35]^B2b.
Subcutaneous ICD (S-ICD): Inappropriate shocks for SVT or occur in 8.1% of patients at 1 year ^[81]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Management of Asymptomatic WPW	ACC/AHA/HRS, Suggests EPS and consideration of ablation for high-risk asymptomatic pre-excitation ^[1]^A1a^[2]^A1a.	Meta-analysis (Obeyesekere et al.), Argues against routine invasive management due to low SCD incidence (1.25/1000 person-years) ^[32]^B2a.	Moderate	Clinical practice varies; clinicians often favor ablation in young patients or those in high-risk professions.
Fluoroscopy Approach	Conventional Fluoroscopy (CF), Standard real-time guidance.	Zero- or Minimal-Fluoroscopy (ZF/MF), Uses electroanatomic mapping to reduce radiation ^[63]^A1a.	Mild	ZF/MF shows equivalent acute success and marginal improvement in long-term success (RR 1.02) ^[63]^A1a.

Pearl: Catheter ablation is the definitive therapy for SVT with success rates exceeding 94%, but clinicians must maintain a 30-minute post-ablation waiting period to reduce the risk of recurrence, particularly in manifest accessory pathways ^[30]^D5^[99]^B3b.

Ablation Outcomes by SVT Subtype

SVT Type	Acute Success Rate	1-Year Recurrence Rate	1-Year Mortality
AVNRT	98.9%	17.2%	<1.4%
Atrial Flutter	96.3% (overall)	32.6% (overall)	2.6%
Focal Atrial Tachycardia	84.3%	32.6% (overall)	2.8%
AVRT	96.3% (overall)	32.6% (overall)	<1.4%

History and Evolution of Treatment

▸The postural modification to the Valsalva maneuver (REVERT technique) significantly improves conversion rates over the standard technique.
▸Flecainide and propafenone are superior to placebo for long-term prophylaxis, though flecainide may be preferred in pediatric populations where digoxin often fails.
▸Intranasal etripamil represents the next generation of on-demand, patient-administered therapy for rapid termination of SVT outside the clinical setting.

HY High Yield: In patients with a history of heart failure or antiarrhythmic use, the likelihood of successful conversion with adenosine is significantly reduced (OR 0.30 and 0.32, respectively) [64].

The of supraventricular tachycardia has transitioned from simple vagal maneuvers to sophisticated pharmacological and interventional strategies. Early clinical practice relied heavily on nonpharmacologic treatments to increase vagal tone, including carotid sinus massage, the diving reflex, and the standard Valsalva maneuver ^[112]^D5. While these remain first-line for hemodynamically stable patients, the standard semi-recumbent Valsalva maneuver often yields low cardioversion rates, typically between 5% and 20% ^[51]^A1b.

Evolution of Vagal Maneuvers

Refinements in physical maneuvers have significantly improved bedside conversion rates without pharmacological intervention. The REVERT trial demonstrated that a postural modification, performing the strain semi-recumbent followed by immediate supine repositioning and passive leg raise, increased sinus rhythm restoration at 1 minute compared to the standard maneuver (43% vs 17%, p < 0.0001) ^[51]^A1b. More recently, the development of handheld Valsalva assist devices has further enhanced efficacy. In a randomized trial, device-assisted maneuvers achieved a 63.2% conversion rate compared to 29.2% for standard maneuvers (p < 0.001) ^[10]^A1b.

Pharmacological Milestones

The introduction of calcium channel blockers and adenosine revolutionized acute termination protocols. was historically the most effective agent for stable patients ^[112]^D5, but became the preferred first-line therapy due to its rapid onset and short half-life. Research into administration routes established that central bolus administration of is more effective than peripheral delivery, with 77% of episodes terminating at a 3 mg dose centrally compared to only 37% at the same dose peripherally ^[109]^A1b.

For long-term prophylaxis, the focus shifted from older agents like , which has been suggested as ineffective in certain pediatric populations ^[121]^B3b, to Class IC antiarrhythmics and beta-blockers. Landmark trials established the efficacy of several agents:

: Demonstrated a 79% actuarial freedom from symptomatic events at 60 days compared to 15% for placebo (p < 0.001) ^[104]^A1b.
: Proved effective at 300 mg BID, though higher doses (300 mg TID) increased adverse events ^[106]^A1b.
and : A single oral dose combination of 120 mg diltiazem and 160 mg propranolol successfully terminated tachycardia in 14 of 15 patients within an average of 27 minutes ^[102]^A1b.

Emergence of Interventional and Novel Therapies

As the limitations of long-term drug therapy became apparent, including a 0.3% to 1.8% mortality risk associated with certain older antiarrhythmics in specific populations ^[115]^D5, catheter-based interventions emerged. Radiofrequency catheter ablation ( ) transformed the treatment of incessant or medically resistant cases, particularly in pediatric patients where it replaced more invasive surgical options ^[124]^C4. In children over 3 years of age, RFA is now considered early in the treatment course because spontaneous resolution of atrial ectopic tachycardia is rare (16%) compared to younger infants (78%) ^[128]^B3b.

Current innovation focuses on non-invasive, on-demand therapies. , a fast-acting intranasal calcium channel blocker, has shown high conversion rates (64% vs 31% for placebo) when self-administered during symptomatic episodes ^[78]^A1b. This represents a shift toward patient-led, out-of-hospital management for recurrent atrioventricular-nodal-dependent tachycardias.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line Pediatric Prophylaxis	is the conventional first choice ^[121]^B3b.	is more effective and should be preferred ^[121]^B3b.	Retrospective ^[121]^B3b	Shift toward Class IC agents in infants.
Acute Adenosine Dosing	Standard 6 mg/12 mg/18 mg peripheral bolus ^[64]^B3b.	Initial 3 mg dose if administered via central line ^[109]^A1b.	Randomized ^[109]^A1b	Lower doses required for central access to avoid heart block.

Pearl: The modified Valsalva maneuver (supine with leg raise) more than doubles the success rate of the standard maneuver (43% vs 17%) and should be the first-line physical intervention ^[51]^A1b.

Comparative Efficacy of Acute Termination Strategies

Intervention	Conversion Rate	Median Time to Conversion	Source
Standard Valsalva	17% to 29.2%	Not reported	^[51]^A1b, ^[10]^A1b
Modified Valsalva	43% to 63.2%	Not reported	^[51]^A1b, ^[10]^A1b
Intranasal Etripamil (70 mg)	64%	17.2 minutes	^[78]^A1b
IV Diltiazem (0.25 mg/kg)	86% to 90%	2 minutes	^[108]^A1b
IV Tecadenoson (300/600 µg)	90%	< 1 minute	^[101]^A1b

Complications

▸SVT is an independent risk factor for adverse pregnancy outcomes, including a nearly six-fold increase in the risk of small-for-gestational-age neonates.
▸Inappropriate ICD shocks triggered by SVT occur in approximately 11.5% of patients and are associated with increased all-cause mortality in certain populations.
▸Malignant progression to ventricular fibrillation occurs in up to 2% of asymptomatic patients with pre-excitation, with the highest risk observed in children.

HY High Yield: In patients with Wolff-Parkinson-White syndrome, the development of 'malignant' atrial fibrillation (shortest RR interval ≤250 ms) is a critical precursor to ventricular fibrillation and sudden cardiac death [1, 2].

! Warning: SVT in the setting of infective endocarditis is a potent predictor of progression to septic shock (OR 3.29), necessitating intensive hemodynamic monitoring [41].

Complications of supraventricular tachycardia (SVT) range from acute hemodynamic collapse and tachycardia-mediated cardiomyopathy to iatrogenic injuries during therapeutic interventions. While often considered benign, the risk of malignant progression is notably higher in patients with pre-excitation or underlying structural heart disease ^[1]^A1a^[2]^A1a.

Arrhythmia-Induced Cardiomyopathy

Chronic or frequent episodes of SVT can lead to tachycardia-mediated cardiomyopathy, a reversible form of dilated cardiomyopathy ^[9]^D5. This condition should be suspected in patients with a mean heart rate >100 beats/min and left ventricular dysfunction ^[9]^D5. Reversal of the cardiomyopathy typically occurs following successful elimination of the arrhythmia via catheter ablation or pharmacotherapy ^[9]^D5^[30]^D5.

Malignant Progression and Sudden Death

In patients with asymptomatic pre-excitation (Wolff-Parkinson-White pattern), the risk of life-threatening events is low but present. Observational cohorts of untreated asymptomatic patients show that malignant (shortest RR interval ≤250 ms) develops in 0% to 9% of cases, while ventricular fibrillation occurs in 0% to 2%, primarily in pediatric populations ^[1]^A1a^[2]^A1a. In the largest pediatric cohort of , symptomatic SVT was a presenting feature in 3.3% of cases, with fever acting as a primary precipitant for subsequent arrhythmic events ^[13]^C4.

Pregnancy and Fetal Complications

SVT during pregnancy is associated with distinct maternal and fetal risks. Maternal SVT is independently linked to an increased risk of preeclampsia (aRR 1.14, 95% CI 1.04-1.24), preterm delivery (aRR 1.76, 95% CI 1.39-2.23), and small-for-gestational-age neonates (aRR 5.93, 95% CI 1.23-28.55) ^[45]^B2a. Fetal SVT can lead to and heart failure; transplacental treatment with or is effective in 89.8% of cases, though serious adverse events occur in approximately 8% of fetuses ^[34]^B2b^[79]^B2b.

Therapy-Related Complications

strategies carry specific risks related to the intervention type:

Inappropriate ICD Shocks: SVT is a common trigger for inappropriate implantable cardioverter-defibrillator (ICD) shocks, accounting for 36% of such episodes ^[38]^B2b. While shocks for SVT do not independently increase mortality (HR 0.97, p = 0.86), they significantly impair quality of life ^[40]^B2b^[88]^D5.
Pharmacotherapy: Intranasal is associated with local adverse events including nasal discomfort (30.2%), congestion (13.9%), and epistaxis (7.4%) ^[25]^B2b. Transplacental sotalol for fetal SVT has a higher failure rate for conversion compared to or ^[79]^B2b.
Ablation Risks: While catheter ablation is highly successful (94.3% to 98.5%), procedural complications such as vagal bradycardia may occur, sometimes requiring concurrent cardioneuroablation ^[26]^A1b^[30]^D5.

Clinical Complication Summary

Complication	Frequency/Risk	Prevention/Management
Tachycardia-Mediated Cardiomyopathy	~1% of PSVT ^[30]^D5	Rate/rhythm control; ^[9]^D5
Inappropriate ICD Shock	11.5% of ICD patients ^[38]^B2b	Enhanced SVT discrimination programming ^[38]^B2b^[88]^D5
Pre-eclampsia (Maternal SVT)	RR 1.46 ^[45]^B2a	Enhanced surveillance for placental insufficiency ^[45]^B2a
Syncope	Higher in BFB + SVT ^[56]^B2b	Pacemaker or loop recorder monitoring ^[11]^A1b^[56]^B2b
Septic Shock (in IE)	OR 3.29 ^[41]^B2b	Aggressive management of infective endocarditis ^[41]^B2b

Pearl: Tachycardia-mediated cardiomyopathy should be considered in any patient with unexplained heart failure and a mean heart rate exceeding 100 beats/min, as the dysfunction is often fully reversible upon rhythm restoration ^[9]^D5.

Clinical Complication Summary

Complication	Frequency/Risk	Prevention/Management
Tachycardia-Mediated Cardiomyopathy	~1% of PSVT ^[30]^D5	Rate/rhythm control; ^[9]^D5
Inappropriate ICD Shock	11.5% of ICD patients ^[38]^B2b	Enhanced SVT discrimination programming ^[38]^B2b^[88]^D5
Pre-eclampsia (Maternal SVT)	RR 1.46 ^[45]^B2a	Enhanced surveillance for placental insufficiency ^[45]^B2a
Syncope	Higher in BFB + SVT ^[56]^B2b	Pacemaker or loop recorder monitoring ^[11]^A1b^[56]^B2b
Septic Shock (in IE)	OR 3.29 ^[41]^B2b	Aggressive management of infective endocarditis ^[41]^B2b

Prognosis and Natural History

▸The risk of sudden cardiac death in asymptomatic Wolff-Parkinson-White syndrome is approximately 1.25 per 1000 person-years, with higher rates observed in children.
▸Catheter ablation provides symptomatic improvement in 74% of patients, though recurrence rates reach 17% for AVNRT and up to 45% for atrial fibrillation at one year.
▸In infants, Wolff-Parkinson-White syndrome and a diagnosis after 60 days of life are the strongest predictors of SVT recurrence.

HY High Yield: In patients with Brugada syndrome or short QT syndrome, SVT is a leading cause of inappropriate ICD shocks, occurring in up to 20% of cases and often requiring specific programming to avoid [14, 18].

The prognosis of supraventricular tachycardia (SVT) is generally favorable in patients with structurally normal hearts, though outcomes vary significantly based on the underlying mechanism and the presence of comorbid conditions. While often considered a benign condition, SVT can serve as a marker for increased risk in specific clinical contexts, such as or congenital heart disease ^[12]^B3b^[41]^B2b.

Natural History and Recurrence

In infants diagnosed with re-entrant SVT at age ≤1 year, the recurrence rate is approximately 33% over a median follow-up of 5.2 years ^[17]^B3b. Risk factors for recurrence in this population include:

Fetal or late diagnosis (>60 days of age) ^[17]^B3b.

In adults, the natural history of asymptomatic pre-excitation involves a low but measurable risk of life-threatening events. The risk of (SCD) in asymptomatic patients is estimated at 1.25 per 1000 person-years ^[32]^B2a. Children with asymptomatic pre-excitation have numerically higher rates of SCD (1.93 per 1000 person-years) compared to adults (0.86 per 1000 person-years) ^[32]^B2a.

Treated Outcomes and Ablation Success

Catheter ablation is highly effective, with a periprocedural success rate of 96.3% across all SVT types ^[42]^B2b. Success rates vary by mechanism:

AVNRT: 98.9% success; 17.2% recurrence at 1 year ^[42]^B2b.
: 2.6% mortality at 1 year; high stroke risk requiring long-term anticoagulation ^[42]^B2b.
Focal Atrial Tachycardia: 84.3% success; 2.8% mortality at 1 year ^[42]^B2b.

Approximately 74.1% of patients perceive ablation as successful at 1 year, and 89.6% of those with recurrence would still undergo a repeat procedure ^[42]^B2b.

Prognostic Significance in Comorbid Disease

SVT often complicates other cardiac or systemic conditions, where it serves as a predictor of poorer outcomes:

: SVT is a common trigger for inappropriate (ICD) shocks, occurring in approximately 20% of patients ^[14]^B2b^[15]^B2b.

Pearl: While SVT is rarely fatal in isolation, its presence in patients with congenital heart disease or infective endocarditis significantly elevates the risk of sudden death or septic shock ^[12]^B3b^[41]^B2b.

SVT Ablation Outcomes by Mechanism

Mechanism	Periprocedural Success	1-Year Recurrence	1-Year Mortality
AVNRT	98.9%	17.2%	<1.4%
Atrial Flutter	Reported	Reported	2.6%
Focal Atrial Tachycardia	84.3%	Reported	2.8%
Atrial Fibrillation	Reported	45.6%	<1.4%

Special Populations and Prevention

▸SVT in pregnancy is a sentinel marker for placental insufficiency and increased risks of preeclampsia, preterm birth, and stillbirth.
▸Zero-fluoroscopy catheter ablation is a highly effective (95.8-97.5% success) and safe intervention for refractory SVT during the second and third trimesters.
▸Wearable digital technology, especially chest-strap monitors, is superior to standard Holter monitoring for capturing exercise-induced SVT in athletes.

HY High Yield: In pregnant patients with symptomatic SVT, an implantable loop recorder (ILR) is significantly more effective than a 24-hour Holter (53% vs 13-24% detection rate) and frequently leads to changes in clinical management [11].

! Warning: Clenbuterol misuse in athletes can trigger refractory SVT and myocardial infarction; it should be suspected in young patients presenting with tachycardia and no structural heart disease [143].

of supraventricular tachycardia (SVT) requires significant modification in specific clinical contexts where physiological changes or comorbidities alter the risk-benefit ratio of standard therapies. While the long-term prognosis is generally favorable, new-onset SVT in high-risk populations often serves as a sentinel event for underlying pathology ^[146]^B2a.

Pregnancy and Peripartum

Pregnancy-associated SVT is increasingly prevalent and associated with significant maternal and fetal morbidity ^[146]^B2a. While often benign, persistent or incessant focal atrial tachycardia (AT) can precipitate and acute decline in left ventricular ejection fraction ^[142]^B2a.

Maternal Outcomes: SVT is independently associated with an increased risk of preeclampsia (aRR 1.14, 95% CI 1.04-1.24) and all-cause maternal mortality (0.78% vs 0.01% in controls; RR 31.94) ^[45]^B2a^[146]^B2a.
Fetal Outcomes: Risks include preterm delivery (aRR 1.76, 95% CI 1.39-2.23), (RR 2.09, 95% CI 1.11-3.91), and small-for-gestational-age neonates (aRR 5.93, 95% CI 1.23-28.55) ^[45]^B2a.
Diagnosis: Implantable loop recorders (ILR) are superior to 24-hour Holter monitoring, detecting arrhythmias in 53% of high-risk pregnant patients compared to 13-24% with Holter alone ^[11]^A1b.
Intervention: Electrical cardioversion and catheter ablation (CA) are safe when medical therapy fails. CA has an acute success rate of 95.8% to 97.5% in pregnancy ^[94]^D5^[142]^B2a. Procedures should utilize zero-fluoroscopy or non-fluoroscopic navigation systems to eliminate fetal radiation exposure ^[89]^C4^[142]^B2a.

Pediatrics

In pediatric populations, SVT may occur as a primary arrhythmia or as a complication of systemic therapy. In a phase 3 trial of pediatric multiple sclerosis, SVT occurred as a serious adverse event in patients treated with intramuscular (30 μg per week) ^[7]^A1b. Management in children requires age-adjusted dosing and consideration of developmental impacts, though curative catheter ablation remains the definitive strategy for recurrent cases ^[89]^C4.

Athletes

Athletes frequently experience paroxysmal SVT that is difficult to document with standard diagnostic modalities because it is often exercise-induced and transient ^[90]^C4.

Detection: Wearable digital devices, particularly chest-strap heart rate monitors and smartwatches, are effective for documenting exercise-induced SVT when conventional Holter monitoring fails ^[90]^C4.
Substance-Induced SVT: Misuse of (doses ranging from 20 μg to 30 mg) by athletes is associated with life-threatening SVT, myocardial injury, and sudden death ^[143]^C4.

Structural Heart Disease and Critical Illness

SVT often complicates existing cardiac or systemic conditions, significantly worsening the prognosis.

Fontan Circulation: Women with Fontan physiology have a 6.59% pooled incidence of SVT during pregnancy, contributing to a 57.31% rate of preterm delivery ^[147]^B2a.
(PPCM): Arrhythmias, including paroxysmal SVT, occur in 17% of PPCM patients within 5 years of diagnosis ^[48]^B2b.

Prevention and Secondary Prophylaxis

Primary prevention focuses on avoiding triggers such as sympathomimetic agents (e.g., ) ^[143]^C4. For secondary prevention, catheter ablation is recommended prior to pregnancy in patients with a known history of SVT to reduce the risk of recurrence and adverse maternal-fetal outcomes ^[89]^C4.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line for Refractory SVT in Pregnancy	Electrical Cardioversion (89.7% success) ^[94]^D5	Catheter Ablation (97.5% success) ^[94]^D5	Moderate	Choice depends on local expertise and fluoroless mapping availability ^[142]^B2a.
Diagnostic Gold Standard	24-hour Holter Monitoring (Standard Care) ^[11]^A1b	Implantable Loop Recorder (Higher sensitivity) ^[11]^A1b	High	ILR leads to management changes in 43% of symptomatic pregnant patients ^[11]^A1b.

Pearl: New-onset SVT in pregnancy or critical illness is rarely an isolated event; it often unmasks occult vascular dysfunction or structural vulnerability, necessitating immediate multidisciplinary evaluation ^[45]^B2a^[146]^B2a.

Maternal and Fetal Risks Associated with SVT

Outcome	Risk Metric (95% CI)	Clinical Significance
Preeclampsia	aRR 1.14 (1.04-1.24)	Increased vascular stress ^[45]^B2a
Preterm Delivery	aRR 1.76 (1.39-2.23)	Most common neonatal complication ^[45]^B2a
Stillbirth	RR 2.09 (1.11-3.91)	Severe fetal compromise ^[45]^B2a
Maternal Mortality	RR 31.94 (unadjusted)	Sentinel event in general population ^[146]^B2a
Septic Shock (in IE)	OR 3.29 (1.14-9.44)	Predictor of critical instability ^[41]^B2b

References

[1]
Al-Khatib SM, Arshad A, Balk EM et al.. “Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.” Circulation (2015). PMID: 26399661 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
[2]
Al-Khatib SM, Arshad A, Balk EM et al.. “Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.” Journal of the American College of Cardiology (2015). PMID: 26409260 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
[3]
Friedman PA, McClelland RL, Bamlet WR et al.. “Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.” Circulation (2006). PMID: 16769912 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[4]
Stambler BS, Dorian P, Sager PT et al.. “Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm.” Journal of the American College of Cardiology (2018). PMID: 30049309 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications
[5]
Wilkoff BL, Ousdigian KT, Sterns LD et al.. “A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.” Journal of the American College of Cardiology (2006). PMID: 16843184 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
[6]
Flyer JN, Zuckerman WA, Richmond ME et al.. “Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation.” Circulation (2017). PMID: 28450351 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[7]
Chitnis T, Arnold DL, Banwell B et al.. “Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.” The New England journal of medicine (2018). PMID: 30207920 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
[8]
Shoureshi P, Tan AY, Koneru J et al.. “Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2024). PMID: 38811098 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
[9]
Huizar JF, Ellenbogen KA, Tan AY et al.. “Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2019). PMID: 31072578 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[10]
Huang L, Sang C, Gao M et al.. “Device-Assisted vs Standard Valsalva Maneuver for Terminating Supraventricular Tachycardia: A Randomized Clinical Trial.” JAMA cardiology (2026). PMID: 41670992 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
[11]
Sliwa K, Azibani F, Johnson MR et al.. “Effectiveness of Implanted Cardiac Rhythm Recorders With Electrocardiographic Monitoring for Detecting Arrhythmias in Pregnant Women With Symptomatic Arrhythmia and/or Structural Heart Disease: A Randomized Clinical Trial.” JAMA cardiology (2020). PMID: 32074256 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Populations and Prevention
[12]
Koyak Z, Harris L, de Groot JR et al.. “Sudden cardiac death in adult congenital heart disease.” Circulation (2012). PMID: 22991410 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
[13]
Probst V, Denjoy I, Meregalli PG et al.. “Clinical aspects and prognosis of Brugada syndrome in children.” Circulation (2007). PMID: 17404158 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Interventional and Device Therapy, Complications, Prognosis and Natural History
[14]
Sacher F, Probst V, Maury P et al.. “Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.” Circulation (2013). PMID: 23995538 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History
[15]
Sacher F, Probst V, Iesaka Y et al.. “Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study.” Circulation (2006). PMID: 17116772 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[16]
Kaneko Y, Naito S, Okishige K et al.. “Atypical Fast-Slow Atrioventricular Nodal Reentrant Tachycardia Incorporating a "Superior" Slow Pathway: A Distinct Supraventricular Tachyarrhythmia.” Circulation (2015). PMID: 26541829 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[17]
Moore JA, Stephens SB, Kertesz NJ et al.. “Clinical Predictors of Recurrent Supraventricular Tachycardia in Infancy.” Journal of the American College of Cardiology (2022). PMID: 36109110 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
[18]
Villafañe J, Atallah J, Gollob MH et al.. “Long-term follow-up of a pediatric cohort with short QT syndrome.” Journal of the American College of Cardiology (2013). PMID: 23375927 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Prognosis and Natural History
[19]
Miyake CY, Del Nido PJ, Alexander ME et al.. “Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia.” Journal of the American College of Cardiology (2011). PMID: 22018302 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
[20]
Moya A, García-Civera R, Croci F et al.. “Diagnosis, management, and outcomes of patients with syncope and bundle branch block.” European heart journal (2011). PMID: 21444367 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[21]
Datino T, Almendral J, González-Torrecilla E et al.. “Rate-related changes in QRS morphology in patients with fixed bundle branch block: implications for differential diagnosis of wide QRS complex tachycardia.” European heart journal (2008). PMID: 18664461 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
[22]
Sawalha K, Pundlik S, Khawaja U et al.. “Safety and outcomes of pulsed field ablation in the management of supraventricular arrhythmia: A systematic review.” Trends in cardiovascular medicine (2025). PMID: 40714216 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Severity Staging and Risk Stratification
[23]
Balweel H, Immanuel SS, Budiono J et al.. “Potential use of ivabradine in postoperative junctional ectopic tachycardia: a systematic review and single-arm meta-analysis.” BMC cardiovascular disorders (2026). PMID: 41845224 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
[24]
Dorian P, Alings M, Coutu B et al.. “Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.” Journal of cardiovascular electrophysiology (2026). PMID: 41668514 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[25]
Ip JE, Coutu B, Ip JH et al.. “Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study.” Journal of cardiovascular electrophysiology (2025). PMID: 40931676 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Complications
[26]
Meng X, Huang S, He L et al.. “Catheter Ablation for Frequent Premature Ventricular Contractions or Paroxysmal Supraventricular Tachycardia With Vagal Bradycardia: A New Clinical Application of Superior Vena Cava-Aorta Ganglionated Plexus Modification.” Clinical cardiology (2026). PMID: 41914517 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
[27]
Bassareo PP, Mihali K, Ciliberti P et al.. “Right atrial appendage aneurysm: an updated systematic review.” Cardiology in the young (2026). PMID: 41540915 ↗
L4SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
[28]
Żuratyński P, Bytner T, Kamińska ET et al.. “Use and effectiveness of the Valsalva maneuver for supraventricular tachycardia in prehospital emergency care: a retrospective cohort study.” BMC emergency medicine (2026). PMID: 41896745 ↗
L3COHORTCited in: Definition, Classification and Nomenclature, Acute and Initial Management, Long-term Guideline-Directed Therapy
[29]
Hughes JW, Olgin JE, Avram R et al.. “Performance of a Convolutional Neural Network and Explainability Technique for 12-Lead Electrocardiogram Interpretation.” JAMA cardiology (2021). PMID: 34347007 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
[30]
Peng G, Zei PC. “Diagnosis and Management of Paroxysmal Supraventricular Tachycardia.” JAMA (2024). PMID: 38497695 ↗
L5OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
[31]
Ni M, Dadon Z, Ormerod JOM et al.. “A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome.” JAMA (2024). PMID: 38900490 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
[32]
Obeyesekere MN, Leong-Sit P, Massel D et al.. “Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis.” Circulation (2012). PMID: 22532593 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[33]
Scirica BM, Morrow DA, Hod H et al.. “Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.” Circulation (2007). PMID: 17804441 ↗
L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[34]
Miyoshi T, Maeno Y, Hamasaki T et al.. “Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.” Journal of the American College of Cardiology (2019). PMID: 31416531 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[35]
Wilkoff BL, Williamson BD, Stern RS et al.. “Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.” Journal of the American College of Cardiology (2008). PMID: 18687248 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[36]
Medi C, Evered L, Silbert B et al.. “Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation.” Journal of the American College of Cardiology (2013). PMID: 23684686 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[37]
Vaseghi M, Boyle NG, Kedia R et al.. “Supraventricular tachycardia after orthotopic cardiac transplantation.” Journal of the American College of Cardiology (2008). PMID: 18534271 ↗
L3OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[38]
Daubert JP, Zareba W, Cannom DS et al.. “Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.” Journal of the American College of Cardiology (2008). PMID: 18387436 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History
[39]
Perino AC, Fan J, Schmitt SK et al.. “Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study.” Journal of the American College of Cardiology (2017). PMID: 28662810 ↗
L3OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Prognosis and Natural History
[40]
Powell BD, Saxon LA, Boehmer JP et al.. “Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.” Journal of the American College of Cardiology (2013). PMID: 23810882 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Interventional and Device Therapy, Complications, Prognosis and Natural History
[41]
Olmos C, Vilacosta I, Fernández C et al.. “Contemporary epidemiology and prognosis of septic shock in infective endocarditis.” European heart journal (2012). PMID: 23060453 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History, Special Populations and Prevention
[42]
Brachmann J, Lewalter T, Kuck KH et al.. “Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.” European heart journal (2017). PMID: 28329395 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
[43]
Wu R, Xing B, Huang Y et al.. “Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 40933383 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Complications
[44]
Chye DM, Sampaio Rodrigues T, Quarto LJG et al.. “Cannabis use and atrial arrhythmias: A systematic review and meta-analysis of large populational studies.” Heart rhythm (2025). PMID: 40472951 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
[45]
Siargkas A, Arvanitaki A, Faka A et al.. “Association of Maternal Cardiac Arrhythmias with Pregnancy Outcomes: A Systematic Review and Meta-Analysis.” Healthcare (Basel, Switzerland) (2026). PMID: 42072894 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Complications, Special Populations and Prevention
[46]
Feng X, Liu J. “Efficacy and safety of adenosine for supraventricular tachycardia: A meta-analysis utilizing BioMedGPT-LM-7B.” BMC cardiovascular disorders (2025). PMID: 40055614 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Prognosis and Natural History
[47]
Liu J, Ding L, Ma W et al.. “Effects of electroacupuncture on the incidence of postoperative supraventricular arrhythmia and sleep quality in patients undergoing thoracoscopic surgery: a randomized controlled trial.” Frontiers in neurology (2025). PMID: 41356247 ↗
L1RCTCited in: Epidemiology and Risk Factors, Prognosis and Natural History
[48]
Moulig V, Pfeffer TJ, Ricke-Hoch M et al.. “Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities.” European journal of heart failure (2019). PMID: 31724271 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention
[49]
Elenizi K, Alharthi R, Alotaibi NE et al.. “Ambulatory Holter Findings in Patients with Palpitations and Structurally Normal Heart: A Prospective Study of the Prevalence and Patterns of Ventricular and Supraventricular Arrhythmias.” Journal of clinical medicine (2026). PMID: 42123017 ↗
L2COHORTCited in: Epidemiology and Risk Factors
[50]
Aegisdottir HM, Andreasen L, Thorolfsdottir RB et al.. “Genome-Wide Association Study of Accessory Atrioventricular Pathways.” JAMA cardiology (2024). PMID: 39230897 ↗
L3OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
[51]
Appelboam A, Reuben A, Mann C et al.. “Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.” Lancet (London, England) (2015). PMID: 26314489 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
[52]
Swerdlow C, Chow T, Das M et al.. “Intracardiac electrogram T-wave alternans/variability increases before spontaneous ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients: a prospective, multi-center study.” Circulation (2011). PMID: 21357826 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Interventional and Device Therapy
[53]
Nakashima K, Yamaguchi T, Takahashi Y et al.. “Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.” European heart journal (2026). PMID: 40996829 ↗
L3OTHERCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[54]
Immanuel SS, Gotama JE, Sayogo Y et al.. “Pursuit of Optimal Vagal Maneuvers in Stable Supraventricular Tachycardia: A Network Meta-Analysis.” The western journal of emergency medicine (2025). PMID: 41380061 ↗
L1SR_OBSCited in: Pathophysiology and Mechanism, Complications
[55]
Appelboam A, Osborne R, Ukoumunne OC et al.. “Evaluation of Out-of-Hospital Use of a Valsalva Assist Device in the Emergency Treatment of Supraventricular Tachycardia.” Annals of emergency medicine (2025). PMID: 40810706 ↗
L1RCTCited in: Pathophysiology and Mechanism, History and Evolution of Treatment, Prognosis and Natural History
[56]
Szaszkiewicz J, Sheldon R, Raj S et al.. “Clinical variables do not predict syncope in pacemaker patients with bifascicular block: a SPRITELY substudy.” Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2025). PMID: 40461610 ↗
L2RCTCited in: Pathophysiology and Mechanism, History and Evolution of Treatment, Complications
[57]
Magor NRE, Elhalafawy SEH, Ads SEM et al.. “Efficacy of modified versus standard Valsalva maneuvers on clinical outcomes and satisfaction of children with paroxysmal supraventricular tachycardia: randomized control trial.” BMC pediatrics (2025). PMID: 41408522 ↗
L1RCTCited in: Pathophysiology and Mechanism, History and Evolution of Treatment, Prognosis and Natural History
[58]
Randa L, Lee C, Cheng J et al.. “Nightly sleep as a predictor of next-day arrhythmias in ambulatory adults.” Journal of electrocardiology (2026). PMID: 42172865 ↗
L2RCTCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
[59]
Gamberini L, Moro F, Dallari C et al.. “Prehospital diagnosis and management of supraventricular tachycardia - a scoping review.” Scandinavian journal of trauma, resuscitation and emergency medicine (2026). PMID: 41723483 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[60]
Mugnai G, Genovese D, Santoro F et al.. “Antiarrhythmics Management During Electrophysiology Procedures: A Stepwise Approach.” Journal of cardiovascular electrophysiology (2026). PMID: 41656175 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[61]
Howard TS, Pham TDN, Valdés SO. “Atrial Tachycardia in the Neonate.” Clinics in perinatology (2025). PMID: 41233008 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[62]
Liu X, Yang L, Cui J et al.. “Experience with patients presenting with the clinical features of Holt-Oram syndrome: a single center retrospective study.” Journal of cardiothoracic surgery (2026). PMID: 41764505 ↗
L4COHORTCited in: Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification
[63]
Khalid A, Samad ZA, Iftikhar A et al.. “Zero- or minimal-fluoroscopy vs conventional fluoroscopy in catheter ablation of supraventricular tachycardias: An updated systematic review and meta-analysis.” Heart rhythm O2 (2026). PMID: 42038666 ↗
L1SR_OBSCited in: Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy
[64]
Şirin İ, Vural NV, Menekşe TS et al.. “Response heterogeneity in patients with vagal-refractory paroxysmal supraventricular tachycardia treated with adenosine: A retrospective study.” The American journal of emergency medicine (2025). PMID: 41448105 ↗
L3COHORTCited in: Diagnosis and Workup, History and Evolution of Treatment
[65]
Oeffl N, Koestenberger M, Sallmon H et al.. “Caffeine and the Young Heart: A Systematic Review of Arrhythmogenic Risks in Children and Adolescents.” Pediatric cardiology (2026). PMID: 42360429 ↗
L1SR_OBSCited in: Diagnosis and Workup
[66]
Ci W, Yawen C, Jiaying W et al.. “Efficacy and safety of acupuncture for arrythmias: an overview of systematic reviews and Meta-analyses.” Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2025). PMID: 41376212 ↗
L1SR_OBSCited in: Diagnosis and Workup
[67]
Thießen N, Olma MC, Tütüncü S et al.. “Holter-ECG findings after acute ischemic stroke and TIA: A systematic analysis of the MonDAFIS randomized trial.” Scientific reports (2026). PMID: 42225709 ↗
L2RCTCited in: Diagnosis and Workup
[68]
Takamiya T, Fujiwara K, Miyamoto T et al.. “Intranodal Atrioventricular Nodal Reentrant Tachycardia Mimicking Junctional Tachycardia.” Journal of cardiovascular electrophysiology (2026). PMID: 42080738 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[69]
Abrahim M, Dilworth N. “Soccer-related blunt chest trauma inducing aberrant supraventricular tachycardia and unmasking Wolff-Parkinson-White syndrome in an adolescent.” Journal of science and medicine in sport (2026). PMID: 41997841 ↗
L4CASE_REPORTCited in: Diagnosis and Workup
[70]
Esmailian A, Alasti M. “Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine.” Frontiers in cardiovascular medicine (2026). PMID: 42291549 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy
[71]
Horvath CM, Fisser C, Floras JS et al.. “Nocturnal Cardiac Arrhythmias in Heart Failure With Obstructive and Central Sleep Apnea.” Chest (2024). PMID: 39168180 ↗
L2RCTCited in: Severity Staging and Risk Stratification
[72]
Younis A, Goldenberg I, McNitt S et al.. “The role and outcomes of new supraventricular tachycardia among patients with mild heart failure.” Journal of cardiovascular electrophysiology (2020). PMID: 32107818 ↗
L2RCTCited in: Severity Staging and Risk Stratification
[73]
Baek SM, Baek JS, Lee J et al.. “Clinical manifestations and outcomes of idiopathic ventricular fibrillation and early repolarization syndrome in adolescents: A multicenter cohort study.” Heart rhythm O2 (2026). PMID: 42183004 ↗
L3COHORTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History
[74]
Vehmeijer JT, Koyak Z, Leerink JM et al.. “Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD).” Heart rhythm (2021). PMID: 33465514 ↗
L2COHORTCited in: Severity Staging and Risk Stratification
[75]
Xiao J, Persson AP, Engström G et al.. “Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.” BMC cardiovascular disorders (2021). PMID: 33711943 ↗
L2COHORTCited in: Severity Staging and Risk Stratification
[76]
Zhang N, Li B, Yan Y et al.. “Infant Kawasaki disease complicated with supraventricular tachycardia: a case report and literature review.” Pediatric rheumatology online journal (2025). PMID: 39939887 ↗
L4CASE_REPORTCited in: Severity Staging and Risk Stratification
[77]
Kulbachinskaya E, Bereznitskaya V. “Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study.” Annals of pediatric cardiology (2024). PMID: 39564160 ↗
L2COHORTCited in: Severity Staging and Risk Stratification
[78]
Stambler BS, Camm AJ, Alings M et al.. “Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.” Lancet (London, England) (2023). PMID: 37331368 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
[79]
Jaeggi ET, Carvalho JS, De Groot E et al.. “Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study.” Circulation (2011). PMID: 21931080 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
[80]
Li Z, Lu Q, Feng R et al.. “Outcomes of Endovascular Repair of Ascending Aortic Dissection in Patients Unsuitable for Direct Surgical Repair.” Journal of the American College of Cardiology (2016). PMID: 27788849 ↗
L4OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy
[81]
Boersma L, Barr C, Knops R et al.. “Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study.” Journal of the American College of Cardiology (2017). PMID: 28797351 ↗
L2OTHERCited in: Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History
[82]
Strum RP, Mondoux S, Dodd T et al.. “Utilization and Metrics Associated with Paramedic Treat and Discharge Medical Directives for Paramedic Services and Emergency Departments: A Retrospective Cohort Study.” Prehospital emergency care (2026). PMID: 42066243 ↗
L3COHORTCited in: Acute and Initial Management
[83]
Ünlütürk S, Kauling RM, Cuypers JAAE et al.. “Outcome 50 years after surgical repair of pulmonary valve stenosis: a longitudinal cohort study.” BMJ open (2026). PMID: 42020122 ↗
L2COHORTCited in: Acute and Initial Management
[84]
Yarnell CJ, Angriman F, Beaubien E et al.. “Association Between Protocolized Magnesium Supplementation and Atrial Fibrillation or Flutter in Critically Ill Patients: A Multicenter Retrospective Cohort Study.” Critical care medicine (2026). PMID: 41612529 ↗
L2COHORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy
[85]
Illahi S, Miah N, Halili A et al.. “Catheter Ablation for SVT in Children < 15 kg and < 5 Years Old: A Systematic Review.” Pediatric cardiology (2026). PMID: 42340448 ↗
L5SR_OBSCited in: Acute and Initial Management, Interventional and Device Therapy
[86]
Satici MO, Aksel G, İslam MM et al.. “Weight-adjusted adenosine and first-dose conversion success in supraventricular tachycardia: a prospective cohort study.” Irish journal of medical science (2026). PMID: 42399571 ↗
L2COHORTCited in: Acute and Initial Management
[87]
Song Y, Zheng Z, Cui K et al.. “Associations between prediabetes, type 2 diabetes, and incident arrhythmias: a population-based cohort study and Mendelian randomization analysis.” Diabetes research and clinical practice (2026). PMID: 42431242 ↗
L2COHORTCited in: Long-term Guideline-Directed Therapy
[88]
Gehi AK, Mehta D, Gomes JA. “Evaluation and management of patients after implantable cardioverter-defibrillator shock.” JAMA (2006). PMID: 17179461 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications
[89]
Xing A, Yan S, Jing K et al.. “Three-dimensional intracardiac ultrasound-guided catheter ablation for pregnancy-associated supraventricular tachycardia: a case report.” BMC pregnancy and childbirth (2026). PMID: 42260398 ↗
L4CASE_REPORTCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Special Populations and Prevention
[90]
Kłopotowski M, Derejko P, Małek Ł. “The Use of Digital Devices in the Management of Athletes with Paroxysmal Arrhythmias During Exercise-A Case Series.” Journal of clinical medicine (2026). PMID: 41899093 ↗
L4CASE_REPORTCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Special Populations and Prevention
[91]
Xu M, Qiu Q, Yan C et al.. “Dual tachycardia in a premature infant: a rare case report and literature review.” Frontiers in cardiovascular medicine (2026). PMID: 41647808 ↗
L4CASE_REPORTCited in: Long-term Guideline-Directed Therapy
[92]
Huang X, Chen F, Wu Y et al.. “Balloon Blowing Facilitates the Termination of Paroxysmal Supraventricular Tachycardia: Comparing the Practicality and Efficacy of Balloon With Syringe-Based Valsalva Maneuver.” Advanced emergency nursing journal (2026). PMID: 41511799 ↗
L1RCTCited in: Long-term Guideline-Directed Therapy
[93]
Al Kaabi S, Mohammed E, Abosalem T et al.. “Arrhythmia Following Congenital Heart Disease Surgery in Oman: Incidence and risk factors - A prospective study.” Sultan Qaboos University medical journal (2026). PMID: 41659221 ↗
L2COHORTCited in: Long-term Guideline-Directed Therapy
[94]
Li W, Hu J, Song H et al.. “Efficacy and safety of electrical cardioversion and catheter ablation during pregnancy: a case review and literature analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42445536 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Special Populations and Prevention
[95]
Gün M. “Pilot Study Comparing Emergency Physician and Artificial Intelligence-supported Interpretations of Electrocardiograms.” The western journal of emergency medicine (2026). PMID: 42258843 ↗
L3OTHERCited in: Long-term Guideline-Directed Therapy
[96]
Zhou W, Shen Y, Tang C et al.. “A Cohort Study on Prognostic Factors for Long-Term Success after Catheter Ablation of Supraventricular Tachycardia in Children.” Cardiology (2026). PMID: 41587147 ↗
L3COHORTCited in: Interventional and Device Therapy
[97]
Ebbinghaus H, Klein N. “Case Report: Pulsed field ablation of an oblique inferoparaseptal accessory pathway.” Frontiers in cardiovascular medicine (2026). PMID: 42058486 ↗
L4CASE_REPORTCited in: Interventional and Device Therapy
[98]
Maksut Z, Esilbaev Z, Bakytzhanuly A et al.. “Case Report: Complex atrial arrhythmia ablation with transbaffle puncture in a Fontan patient with intracardiac lateral tunnel anatomy.” Frontiers in cardiovascular medicine (2026). PMID: 42028230 ↗
L4CASE_REPORTCited in: Interventional and Device Therapy
[99]
Boyd CA, Bruno MA, Lodeiro CA et al.. “Detection of Accessory Pathway Recurrence at Standard and Abbreviated Waiting Periods and Implications for Recurrence Following Pediatric Radiofrequency Ablation.” Journal of cardiovascular electrophysiology (2026). PMID: 42462080 ↗
L3OTHERCited in: Interventional and Device Therapy
[100]
Mizutani A, Okada M, Mizutani M et al.. “Induction indices during ventricular pacing as an alternative diagnostic tool in supraventricular tachycardias.” Heart rhythm O2 (2026). PMID: 42183006 ↗
L3OTHERCited in: Interventional and Device Therapy
[101]
Ellenbogen KA, O'Neill G, Prystowsky EN et al.. “Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson.” Circulation (2005). PMID: 15956124 ↗
L1RCTCited in: History and Evolution of Treatment
[102]
Yeh SJ, Lin FC, Chou YY et al.. “Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol.” Circulation (1985). PMID: 3964710 ↗
L1RCTCited in: History and Evolution of Treatment
[103]
. “Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators.” Circulation (1997). PMID: 9355903 ↗
L1RCTCited in: History and Evolution of Treatment
[104]
Henthorn RW, Waldo AL, Anderson JL et al.. “Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.” Circulation (1991). PMID: 1898640 ↗
L1RCTCited in: History and Evolution of Treatment
[105]
White HD, Antman EM, Glynn MA et al.. “Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery.” Circulation (1984). PMID: 6378423 ↗
L1RCTCited in: History and Evolution of Treatment
[106]
. “A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.” Circulation (1995). PMID: 7586356 ↗
L1RCTCited in: History and Evolution of Treatment
[107]
Anderson JL, Gilbert EM, Alpert BL et al.. “Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.” Circulation (1989). PMID: 2513143 ↗
L1RCTCited in: History and Evolution of Treatment
[108]
Huycke EC, Sung RJ, Dias VC et al.. “Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, multicenter study.” Journal of the American College of Cardiology (1989). PMID: 2918157 ↗
L1RCTCited in: History and Evolution of Treatment
[109]
McIntosh-Yellin NL, Drew BJ, Scheinman MM. “Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia.” Journal of the American College of Cardiology (1993). PMID: 8354807 ↗
L1RCTCited in: History and Evolution of Treatment
[110]
Chimienti M, Cullen MT, Casadei G. “Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.” European heart journal (1995). PMID: 8682031 ↗
L1RCTCited in: History and Evolution of Treatment
[111]
Patel DJ, Purcell HJ, Fox KM. “Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization.” European heart journal (1999). PMID: 10075141 ↗
L1RCTCited in: History and Evolution of Treatment
[112]
Ornato JP. “Management of paroxysmal supraventricular tachycardia.” Circulation (1986). PMID: 3536156 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[113]
Cruickshank JM, Neil-Dwyer G, Degaute JP et al.. “Reduction of stress/catecholamine-induced cardiac necrosis by beta 1-selective blockade.” Lancet (London, England) (1987). PMID: 2887885 ↗
L1RCTCited in: History and Evolution of Treatment
[114]
Campbell RW. “Supraventricular tachycardia. Occasional nuisance or frequent threat?” European heart journal (1996). PMID: 8809535 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[115]
Reimold SC. “Avoiding drug problems. The safety of drugs for supraventricular tachycardia.” European heart journal (1997). PMID: 9152674 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[116]
Brown MA, Smith WM, Lubbe WF et al.. “Amiodarone-induced torsades de pointes.” European heart journal (1986). PMID: 3709557 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[117]
Kunze KP, Schlüter M, Kuck KH. “Sotalol in patients with Wolff-Parkinson-White syndrome.” Circulation (1987). PMID: 3568305 ↗
L4OTHERCited in: History and Evolution of Treatment
[118]
Leitch JW, Klein GJ, Yee R et al.. “Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response?” Circulation (1992). PMID: 1537103 ↗
L4OTHERCited in: History and Evolution of Treatment
[119]
Irwin JM, McCarthy EA, Wilkinson WE et al.. “Circadian occurrence of symptomatic paroxysmal supraventricular tachycardia in untreated patients.” Circulation (1988). PMID: 3338126 ↗
L2OTHERCited in: History and Evolution of Treatment
[120]
Clair WK, Wilkinson WE, McCarthy EA et al.. “Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients.” Circulation (1993). PMID: 8462140 ↗
L2OTHERCited in: History and Evolution of Treatment
[121]
O'Sullivan JJ, Gardiner HM, Wren C. “Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?” Journal of the American College of Cardiology (1995). PMID: 7560629 ↗
L3OTHERCited in: History and Evolution of Treatment
[122]
Haines DE, DiMarco JP. “Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up.” Journal of the American College of Cardiology (1990). PMID: 2329238 ↗
L4OTHERCited in: History and Evolution of Treatment
[123]
Kushner JA, Kou WH, Kadish AH et al.. “Natural history of patients with unexplained syncope and a nondiagnostic electrophysiologic study.” Journal of the American College of Cardiology (1989). PMID: 2754128 ↗
L2OTHERCited in: History and Evolution of Treatment
[124]
Case CL, Gillette PC, Oslizlok PC et al.. “Radiofrequency catheter ablation of incessant, medically resistant supraventricular tachycardia in infants and small children.” Journal of the American College of Cardiology (1992). PMID: 1430691 ↗
L4OTHERCited in: History and Evolution of Treatment
[125]
Secknus MA, Marwick TH. “Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years.” Journal of the American College of Cardiology (1997). PMID: 9137218 ↗
L2OTHERCited in: History and Evolution of Treatment
[126]
McKenna WJ, Franklin RC, Nihoyannopoulos P et al.. “Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy.” Journal of the American College of Cardiology (1988). PMID: 3335690 ↗
L4OTHERCited in: History and Evolution of Treatment
[127]
Fenrich AL, Perry JC, Friedman RA. “Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.” Journal of the American College of Cardiology (1995). PMID: 7897134 ↗
L4OTHERCited in: History and Evolution of Treatment
[128]
Salerno JC, Kertesz NJ, Friedman RA et al.. “Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children < 3 or > or =3 years of age.” Journal of the American College of Cardiology (2004). PMID: 15013128 ↗
L3OTHERCited in: History and Evolution of Treatment
[129]
Levy S. “Differentiating SVT from VT--a personal viewpoint.” European heart journal (1994). PMID: 8070495 ↗
L5OTHERCited in: History and Evolution of Treatment
[130]
McKenna WJ. “Arrhythmia and prognosis in hypertrophic cardiomyopathy.” European heart journal (1983). PMID: 6686539 ↗
L5OTHERCited in: History and Evolution of Treatment
[131]
Perrot B, Cherrier F, Faivre G. “Significance of supraventricular arrhythmias induced by electrophysiologic studies.” European heart journal (1984). PMID: 6734639 ↗
L3OTHERCited in: History and Evolution of Treatment
[132]
Lindinger A, Heisel A, von Bernuth G et al.. “Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults.” European heart journal (1998). PMID: 9651719 ↗
L4OTHERCited in: History and Evolution of Treatment
[133]
Brugada P, Wellens HJ. “Long-term follow-up of incessant supraventricular tachycardia treated with oral encainide.” European heart journal (1987). PMID: 3111853 ↗
L4OTHERCited in: History and Evolution of Treatment
[134]
Schafer B, Steidl KE, Burgess JL et al.. “Comparison of Adenosine Administration Utilizing a Single-Syringe Versus a Double-Syringe Method in a Simulated Pediatric Patient.” Pediatric emergency care (2025). PMID: 41178114 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
[135]
Al Riyami H, Zamzami S, Hornberger LK et al.. “Does a Smartphone-Based ECG Recording System in Pediatric Patients With Palpitations Improve Diagnostic Yield?” Pacing and clinical electrophysiology : PACE (2025). PMID: 40285525 ↗
L1RCTCited in: History and Evolution of Treatment
[136]
Camp S, Elhamdani A, Zinabu S et al.. “Serum troponin testing and adverse cardiovascular outcomes in supraventricular tachycardia: A retrospective study from TriNetX.” The American journal of emergency medicine (2025). PMID: 40349636 ↗
L3COHORTCited in: History and Evolution of Treatment
[137]
Leng T, Aldalati A, Homme JL. “Utility of Holter monitoring in pediatric patients with arrhythmia symptoms in the ED: A retrospective cohort study.” The American journal of emergency medicine (2025). PMID: 40117829 ↗
L3COHORTCited in: History and Evolution of Treatment
[138]
Chen X, Cao Y, Li H et al.. “Comparative study of traditional versus nurse-assisted modified Valsalva maneuver for treating paroxysmal supraventricular tachycardia in orthopedic patients with limited lower limb activity.” Medicine (2025). PMID: 40324261 ↗
L1RCTCited in: History and Evolution of Treatment
[139]
Jha M, Song D, Kung A et al.. “Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials.” Journal of clinical medicine (2025). PMID: 40507484 ↗
L1SR_MA_RCTCited in: Complications
[140]
Arrighini GS, Dandamudi M, Ho VQT et al.. “Pulsed field ablation for paroxysmal supraventricular tachycardia: a systematic review and single-arm meta-analysis.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2025). PMID: 41269503 ↗
L1SR_OBSCited in: Complications
[141]
Joglar JA, Kapa S, Saarel EV et al.. “2023 HRS expert consensus statement on the management of arrhythmias during pregnancy.” Heart rhythm (2023). PMID: 37211147 ↗
L1GUIDELINECited in: Special Populations and Prevention
[142]
Ventrella N, Schiavone M, Bianchini L et al.. “Catheter ablation for focal atrial tachycardias during pregnancy: A systematic review.” International journal of cardiology (2024). PMID: 38972492 ↗
L2SR_OBSCited in: Special Populations and Prevention
[143]
Kumari S, Pal B, Sahu SK et al.. “Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.” International journal of legal medicine (2023). PMID: 37062796 ↗
L4SR_OBSCited in: Special Populations and Prevention
[144]
Gerede A, Daskalakis G, Mikos T et al.. “Safety of COVID-19 Vaccination in Pregnancy: A Systematic Review.” Diagnostics (Basel, Switzerland) (2024). PMID: 39202263 ↗
L5SR_OBSCited in: Special Populations and Prevention
[145]
Bai Y, Qiu J, Hu M et al.. “Emergent Zero-Fluoroscopy Mapping and Thoracoscopic Ectomy of Appendage in Pregnant Women with Life-Threatening Atrial Tachycardia: A Case Report and Literature Review.” Medicina (Kaunas, Lithuania) (2023). PMID: 36984528 ↗
L4CASE_REPORTCited in: Special Populations and Prevention
[146]
Siargkas A, Arvanitaki A, Faka A et al.. “Impact of Cardiac Arrhythmias on Acute Maternal Cardiovascular Outcomes in Pregnancy: A Systematic Review and Meta-Analysis.” Life (Basel, Switzerland) (2026). PMID: 41752914 ↗
L2SR_OBSCited in: Special Populations and Prevention
[147]
Attachaipanich T, Attachaipanich S, Kaewboot K. “Pregnancy outcomes in Fontan circulation: a systematic review and meta-analysis.” Proceedings (Baylor University. Medical Center) (2025). PMID: 40557230 ↗
L2SR_OBSCited in: Special Populations and Prevention
[148]
Hallmark AK, Lindley KJ, Banayan JM. “Peripartum management of cardiac arrhythmias: a narrative review.” International journal of obstetric anesthesia (2024). PMID: 39241680 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification, and Nomenclature

Synonyms and Abbreviations

Classification and Mechanisms

Nomenclature and Clinical Variants

Epidemiology and Risk Factors

Demographic Distribution

Risk Factors and Clinical Drivers

Genetic and Structural Predispositions

Temporal and Procedural Trends

Pathophysiology and Mechanism

Reentrant Mechanisms

Focal and Triggered Mechanisms

Autonomic and Environmental Modifiers

Tachycardia-Induced Remodeling

Mechanism flowchart

Clinical Presentation

Presenting Symptoms

Physical Examination Findings

Phenotypic Variants and Special Populations

Red Flags and Complications

ECG Findings

Diagnosis and Workup

History and Physical

ECG Findings

Laboratory and Imaging

Gold-Standard Test: Electrophysiological Study (EPS)

Diagnostic Algorithm

Severity Staging and Risk Stratification

Asymptomatic Pre-excitation

Prognostic Scores and Risk Models

Risk of Atrial Fibrillation and Mortality

ECG Findings in Risk Stratification

Acute and Initial Management

Step 1: Hemodynamic Assessment and Vagal Maneuvers

Step 2: First-Line Pharmacological Therapy

Step 3: Second-Line and Refractory Management

Step 4: Special Clinical Contexts

Controversies and Guideline Disagreement

Long-term Guideline-Directed Therapy

Catheter Ablation

Pharmacological Prophylaxis

Management in Special Populations

Controversies and Guideline Disagreement

Interventional and Device Therapy

Step 1: Electrophysiological Study and Risk Stratification

Step 2: Catheter Ablation

Step 3: Device Programming and Management

Controversies and Guideline Disagreement

History and Evolution of Treatment

Evolution of Vagal Maneuvers

Pharmacological Milestones

Emergence of Interventional and Novel Therapies

Controversies and Guideline Disagreement

Complications

Arrhythmia-Induced Cardiomyopathy

Malignant Progression and Sudden Death

Pregnancy and Fetal Complications

Therapy-Related Complications

Clinical Complication Summary

Prognosis and Natural History

Natural History and Recurrence

Treated Outcomes and Ablation Success

Prognostic Significance in Comorbid Disease

Special Populations and Prevention

Pregnancy and Peripartum

Pediatrics

Athletes

Structural Heart Disease and Critical Illness

Prevention and Secondary Prophylaxis

Controversies and Guideline Disagreement

References

Step 3: Second-Line and Refractory